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ABSTRACT

Secretion of toxins into host cells is an important component of microbial
pathogenesis. In order to gain access to the host cell cytosol, toxins must cross the
plasma membrane, traverse the membrane of endocytic vesicles, or cross the membrane
of organelles. The process cytolysin-mediated translocation (CMT) in Streptococcus
pyogenes uses the pore-forming protein streptolysin O (SLO) to translocate the S.
pyogenes NAD+-glycohydrolase (SPN) effector into the cytosol of eukaryotic host cells.
Although, the fundamentals of this protein translocation process are established the
details of the mechanism remain elusive.
The current studies illustrate that the translocation process is more complex than
initially projected. It was thought that the effector protein, SPN, entered the host cell
cytosol through the lumen of the translocator, SLO. In this thesis, mutational analysis
demonstrates that SPN translocation into the host cell does not require SLO pore
formation. Furthermore, the SLO pore-forming mutant and wild type strains use an
indistinguishable pathway to translocate SPN.

While the pore-forming mutant can

translocate SPN, the cytotoxic affects of CMT occur only when SLO forms pores and
translocates SPN.

These studies illustrate that SLO pore formation can occur

independently of SPN secretion and that there is a synergistic effect between these two
SLO activities.

Further studies using pharmacological inhibitors to probe the

involvement of the host cell during CMT indicate that clathrin-dependent endocytosis
does not play a role. The carboxyl-terminus of SLO makes contact with the host cell
membrane through an area denoted as Domain 4.
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Mutational studies indicate that

expression of Domain 4 from the related pore-forming protein, perfringolysin O (PFO), is
insufficient for CMT. Moreover, CMT is unaffected by extraction of cholesterol to levels
that block membrane binding by the cholesterol-dependent PFO protein.

Although

cholesterol is unnecessary, mutations that interrupt cholesterol binding by SLO indicate
the sterol does increase the efficiency of CMT. Furthermore, a loop region within
Domain 4 is important and provides SLO with its specificity in CMT. Taken together,
even though SLO binds to cholesterol, there might be an additional membrane receptor
necessary for CMT. In total, the research described in this thesis furthers the knowledge
of the CMT mechanism and provides opportunities for future investigation into the role
of CMT in infections.
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Chapter I

Introduction

1

Classification of Streptococcus

Bacteria classified within the genus Streptococcus are members of the phylum
Firmicutes and the lactic acid group of bacteria. Streptococci are facultative anaerobic
Gram-positive bacteria that are non-motile, have a spherical shape, and form chains (11).
Streptococci are categorized according to their intrinsic hemolytic property. Alphahemolytic streptococci do not lyse red blood cells, but appear greenish in color on blood
agar plates due to the reduction of iron in hemoglobin. Gamma-hemolytic streptococci
do not have the ability to rupture or affect red blood cells. Beta-hemolytic streptococci
are able to completely lyse red blood cells to produce a zone of clearance on blood agar
plates generally because of the secreted toxin Streptolysin S.

The beta-hemolytic

streptococci are further distinguished by the presence of specific carbohydrates on their
bacterial surface, which are identified using Lancefield serotyping (52).
Streptococcus pyogenes is a beta-hemolytic and Lancefield Group-A bacterium.
Additional classification of Group A streptococci occurs based on the type of M protein
adhesin present on the surface of the bacterium (Figure 1). These adhesins have a central
and conserved C-terminal domain anchored to the S. pyogenes cell wall via an LPXTG
motif (15, 24, 63). The N-terminal region of M protein, described as the hyper-variable
domain, is the source of the diversity in this family of proteins used to classify the M type
(15, 24, 63). Currently, there are over 180 types of M protein known, with M1 and M12
being the most prevalent in the United States (94, 98).
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Figure 1. The structure of the S. pyogenes M protein adhesin. The carboxyl terminus of the
adhesin is attached to the bacterial cell membrane. Each M type adhesin is distinctive because
the amino terminus of the protein contains a variable region, which is encoded by many different
sequences. Adapted from Ref. (24).
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Diseases and the prevalence of S. pyogenes

S. pyogenes is a bacterial pathogen that can infect both soft and deeper tissues
resulting in non-invasive and invasive diseases, respectively. Diseases that occur due to
an infection with S. pyogenes can be suppurative (pus forming) or non-suppurative
sequelae. The suppurative infections can arise from both non-invasive and invasive
diseases (17). The ability of S. pyogenes to infect many organs allows it to cause a wide
array of ailments (Figure 2).

Figure 2. The pathogenesis of S. pyogenes infections in humans. The various organs that S.
pyogenes can infect and the resulting diseases are shown. Adapted from Ref. (75).
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Clinical manifestations of an S. pyogenes infection range from mild and selflimiting to those that are severe and life threatening. Soft tissue infection sites including
the mucous membranes, tonsils, and skin are suppurative infections that lead to noninvasive diseases such as pharyngitis (strep throat) and impetigo (17). These diseases are
typically treated using antibiotics such as penicillin and cephalosporins, though penicillin
is the preferred option.
Deep tissue S. pyogenes infections can cause severe and invasive diseases which
include necrotizing fasciitis, streptococcal toxic shock syndrome, sepsis, and meningitis
(17). These deep tissue infections can be suppurative infections that do not respond to
penicillin and can ultimately lead to death. Post-infectious sequelae, for instance acute
rheumatic fever and glomerulonephritis, develop as a result of a previous S. pyogenes
infection that was not adequately treated (18). The onset of acute rheumatic fever is
generally accompanied by autoimmune diseases such as rheumatic heart disease,
rheumatic

arthritis,

or

the

neurological

disease

Sydenham

chorea

(18).

Glomerulonephritis is characterized by inflammation of blood vessels in the kidney and
eventual renal failure (18).
While S. pyogenes can cause post-infectious and invasive disease, the archetypal
infection manifests as a non-invasive disease. Annually, it is estimated that there are over
700 million cases of S. pyogenes infections worldwide that cause superficial diseases
(e.g., pharyngitis) (12). According to the Centers for Disease Control and Prevention, in
the United States there are greater than 10 million infections that cause mild diseases like
pharyngitis and the majority of these infections occur in school-age children (1).
However, non-invasive disease can occur in all age groups, including adults who live in
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close quarters such as dormitories and military barracks (17). In comparison to the noninvasive disease statistics, the numbers of severe disease worldwide and in the U.S. are
far fewer. Globally there are around 18 million cases of invasive and post-infectious
disease with approximately 2 million new cases each year (12). In the United States,
there are approximately 9,000 to 11,500 S. pyogenes infections that lead to invasive
disease and ultimately 1,000 to 1,800 individuals die as a result (1). Even though S.
pyogenes has the ability to infect multiple organs, in total, these statistics suggest that the
development of severe disease is rare. Thus, the typical S. pyogenes infection does not
end with death, which potentially allows the bacteria to infect other individuals in the
population.
There is evidence indicating that the nasopharynx serves as the location of the S.
pyogenes reservoir (72). S. pyogenes is an exclusively human pathogen and there are
potentially two reservoir populations. Individuals (e.g., children) treated with antibiotics
for pharyngitis and tonsillitis, but who continue to develop recurrent S. pyogenes
infections, might be one possible reservoir population (73, 74). Alternatively, a second
reservoir population may consist of individuals who are asymptomatically colonized (62).
An anomalous fact is that as many as 30% of individuals who receive penicillin do not
successfully clear a S. pyogenes infection (89). Additionally, the only known antibiotic
resistance is towards macrolides (erythromycin) and not penicillin (6, 26). Some of the
individuals that do not respond to antibiotics have active recurrent infections, while
others are culture positive without any symptoms.
The current model for the formation of the S. pyogenes reservoirs suggests that
bacteria can invade host epithelial cells and thereby resist antibiotics and host defenses
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until conditions improve. Previous work shows that several strains of S. pyogenes,
collected from infected individuals, are able to adhere and invade epithelial cells grown
in vitro culture, in medium containing antibiotics for at least 4 days (56, 71, 89).
Additionally, removal of the antibiotics initiates the release of S. pyogenes from the
epithelial cells and allows extracellular bacteria growth to resume (71). There are also
reports that suggest the genes necessary for encoding specific adhesins are present in S.
pyogenes strains isolated from individuals with recurrent infections and from
asymptomatic individuals (62, 64).

Histological sections of S. pyogenes infected

epithelial cells show adherent and intracellular bacteria (72).

Electron microscopy

images of tissue sections, from recurrently infected and asymptomatic individuals,
indicate that S. pyogenes is present in the epithelial cells of the tonsils and pharynx (72,
73). A recent report states that the S. pyogenes genome is present in tissue sections from
individuals with recurrent tonsillitis (95). However, attempts to culture S. pyogenes from
the infected tissues were unsuccessful even though several non-related bacterial species
did grow from the same samples (95). Taken together, this data supports the notion that
S. pyogenes is present in tissue samples, but the inability to culture the bacteria suggests
the organisms might not be viable. There is an abundant amount of data indicating that S.
pyogenes can enter cells to evade clearance and antibiotic treatment, however, further
work is necessary to assess the capacity of these bacteria to reestablish infections.

7

Adhesins on the surface of S. pyogenes

The ability of S. pyogenes to infect various types of tissue and cause disease
depends on its effective adherence to human cells. There are approximately twenty
different adhesins identified for S. pyogenes (15).

The expression of these various

adhesins differs by strain and by the environmental conditions in which the bacterium
grows (15). Three major adhesins present on the surface of S. pyogenes that facilitate
binding are the M protein, fibronectin binding protein (Protein F or Sfb), and lipoteichoic
acid.
M protein, which is encoded by the emm gene, is secreted and covalently
anchored to the cell membrane via an LPXTG motif present in the carboxyl terminus
(24). Two M protein polypeptides then assemble on the surface of S. pyogenes to form a
fibrous alpha helical coiled-coiled protein (Figure 1). Each M protein has a carboxyl
terminus that contains a conserved C repeat domain and an amino terminus that contains
highly variable sequence (24). The conserved C repeat domain is necessary for M
protein to bind to CD46, a membrane cofactor protein present on keratinocytes (skin
cells) and lung epithelial cells, as demonstrated by the inability of S. pyogenes strains
lacking M protein or lacking the C repeat domain to bind to keratinocytes (69, 70, 82).
Additionally, Lactococcus lactis binds CD46 on the surface of lung epithelial cells when
M protein is heterologously expressed (82). Previous reports show that M protein can
also bind fibrinogen, fucose-glycoproteins, and sialic acid modified proteins (15). The
amino terminus of M protein is also known to confer antiphagocytic properties to S.
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pyogenes (24). M protein is therefore a versatile adhesin that protects S. pyogenes and
permits the bacterium to bind to various cell types.
There are many adhesins on the surface of S. pyogenes dedicated to binding the
extracellular matrix components such as fibronectin, vitronectin, collagen, integrins,
laminin, and heparin sulfate (15). Fibronectin, a large extracellular matrix glycoprotein
that binds to integrin receptors present in the membrane of human cells, is widely used as
a receptor for S. pyogenes adhesions(15). Furthermore, fibronectin binding proteins are
important for adherence to many different cell types (15).

At least five different

fibronectin binding proteins in S. pyogenes are covalently attached to the bacterial cell
wall via an LPXTG motif and contain a binding domain that is made of repeating units
(Figure 3) (88).

These repeating units significantly increase the ability of the five

proteins to bind to fibronectin (88). Protein F is the first member of this protein family
identified in S. pyogenes; this protein is able to bind soluble and insoluble fibronectin (16,
35). In addition to the five proteins with the fibronectin binding domain, S. pyogenes
expresses a number of other adhesins that can bind to fibronectin including lipoteichoic
acid. A two-step binding method might be important for S. pyogenes adherence, with
lipoteichoic acid making the initial contact with the host cell membrane followed by
another adhesion binding to its receptor (15). The diverse number of adhesins anchored
to the S. pyogenes cell wall provides the bacteria the access necessary to adhere to and
infect various human cells.
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Toxins and Enzymes Secreted from S. pyogenes

During the course of an infection, S. pyogenes secretes over 40 toxic proteins and
enzymes that are important for survival within the host (23, 60). The streptococcal
pyrogenic exotoxins, also known as superantigens, are a large family of secreted proteins
that are extremely perilous (5, 7). These proteins uncontrollably stimulate T cells to
induce a massive immune response and lead to the disease state known as streptococcal
toxic shock syndrome. Other secreted proteins help S. pyogenes evade the immune
system. The serine protease streptococcal C5a peptidase, anchored to the bacterial cell
wall, can cleave the human protein C5a to prevent immune cell recruitment, allowing the
bacteria to continue proliferating (11).

Enzymes such as hyaluronidase and DNase

secreted by S. pyogenes may help the bacteria gather nutrients and spread the infection (7,
11). Several other enzymes play a key role in the capability of the S. pyogenes infection
to spread through the tissue (Figure 4). Streptokinase disintegrates clots by converting
plasminogen to plasmin and glucuronidase can degrade glycosaminoglycans found in the
extracellular matrix. The secreted cysteine protease SpeB cleaves both host and bacterial
proteins.

SpeB release of streptococcal proteins from the bacterial surface and

degradation of streptococcal proteins present in the extracellular milieu may assist S.
pyogenes evasion of the immune system (13).
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Streptolysin S

Figure 4. Toxins and enzymes secreted by Streptococcus pyogenes. Over 40 proteins are
secreted during an S. pyogenes infection to support nutrient acquisition, bacterial replication, and
immune evasion. Listed here are examples of those proteins (5, 7, 11).

Streptolysin O and S are two hemolysins that possess an ability to lyse and harm
structures in the body including erythrocytes, polymorphonuclear leucocytes, organelles,
and tissues. The hemolysis observed on blood agar plates is mostly due to the secretion
of Streptolysin S (SLS). SLS is a small-modified peptide that is non-immunogenic,
oxygen-stable, and associates with the bacterial cell wall. Delivery and toxicity of the
SLS is optimal when S. pyogenes is in contact with the target (11, 66). Additionally, the
production of SLS allows S. pyogenes to circumvent the host immune response and
prevent the recruitment of neutrophils (53). Streptolysin O forms oligomeric pores in the
membrane of mammalian cells. The following section will provide further information
about this hemolytic toxin.

12

Cholesterol-dependent Cytolysins

Gram-positive pathogenic bacteria secrete many pore-forming toxins including
the cholesterol-dependent cytolysins (CDC).

Over 20 species, including the genera

Streptococcus, Clostridium, Listeria, Bacillus, and Arcanobacterium, secrete these poreforming proteins, which have 40-70% amino acid sequence similarity (91). The CDC’s
are large oligomers consisting of 35 to 50 cytolysin monomers that produce beta-barrel
pores ranging in size from 25 to 30 nm in diameter (38). The resolved three-dimensional
structure of three members of the CDC family – perfringolysin O from Clostridium
perfringens, intermedilysin from Streptococcus intermedius, and anthrolysin O from
Bacillus anthracis – demonstrate that each soluble cytolysin folds into four discontinuous
domains (8, 77, 85) (Figure 5).

Figure 5. Perfringolysin O, intermedilysin, and anthrolysin O monomer structures. The
ribbon diagrams illustrate the structure of three members of the CDC protein family. Four
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discontinuous domains are visible in all three cytolysin protein monomers. Domain 4 makes
contact with the host cell membrane and domain 3 contains two sets of three α-helices that
become transmembrane-β-hairpins, which insert into the membrane. Adapted from Refs. (8,
100).

The structural similarity between the three cytolysins suggests that the other
members of the CDC protein family likely have a similar arrangement and pore forming
mechanism (Figure 5).

Extensive research conducted with perfringolysin O (PFO)

provides details regarding the mechanism of pore formation (Figure 6). Water soluble
cytolysin monomers secreted from the bacteria initially bind to the surface of the host cell
via domain 4 of the protein (100). As the monomers bind, only the tip of domain 4
inserts into the host cell membrane and each monomer is perpendicular to the membrane
(37, 79, 81). In each cytolysin monomer, domain 3 has two sets of three short α-helices.
The primary domain 4 binding event triggers movement of a short β strand in domain 3
of each monomer and disrupts hydrogen bond interactions between the short β strand and
a short α-helix (Figure 7) (81). This movement in domain 3 reveals the interface through
which the cytolysin monomers can interact (81). Once the short β strand in domain 3
moves, the two sets of the three short α-helices undergo a conformation change and
become two transmembrane-β-hairpins (strands β1 – β4, Figure 7) (81, 90, 91). The β1
strand of the β-hairpin from one cytolysin monomer interacts with the β4 strand of the βhairpin from the adjacent monomer (Figure 7) (81).
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Figure 6. Mechanism of cytolysin pore formation. The structural domains of the cytolysin are
numbered. Stage I: Each soluble cytolysin monomer binds to the membrane via the carboxyl
terminus (domain 4). Stage II: A series of conformational changes throughout the structure of
each cytolysin initiates oligomerization to form the multimeric prepore complex on the surface of
the membrane. Stage III: Additional structural movements within each monomer of the prepore
complex leads to the vertical collapse of domain 1 and domain 2, which permits the insertion of
the domain 3 transmembrane-β-hairpins into the membrane to form a large β-barrel pore.
Adapted from (38).

15

Figure 7. Formation of the cytolysin transmembrane-β-hairpins. The structure of domain 3
at each stage of pore formation is shown. Stage I: Two sets of three α-helices are present in each
cytolysin monomer. Stage II: Once the cytolysins bind to the membrane, a short β strand (β5) in
domain 3 shifts to reveal the monomer-monomer interaction surface, which will initiate formation
of the prepore complex. Stage III: In each cytolysin monomer, the two sets of three short αhelices unravel to form two transmembrane-β-hairpins, which will insert into the membrane to
form a pore. The β1 strand of from a cytolysin monomer interacts with the β4 strand of the
adjacent cytolysin monomer. Adapted from (38).

As the monomers form hydrogen bonds between each other on the surface of the
membrane an oligomeric structure, known as the prepore complex, forms (Figure 6) (37,
40-42, 92). The prepore complex sits on the surface of the membrane (19). Formation of
the prepore complex is the rate-limiting step of cytolysin pore formation and the two βhairpins of each monomer can insert into the membrane once assembly of the complex is
complete (42, 43).

Insertion of the domain 3 transmembrane-β-hairpins involves

movement of domain 1 closer to the membrane, bending of the β sheets in domain 2, and
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a 40 Å vertical collapse of the prepore complex into the membrane, which results in the
formation of a large transmembrane β-barrel (Figure 6) (19, 20, 80).
The interaction between domain 4 and the membrane requires further
investigation because the receptor for many of the cytolysins is unknown. Recent studies
reveal that domain 4 of each cytolysin binds to cholesterol and possibly a separate
receptor. Pore formation by PFO, streptolysin O and intermedilysin (ILY) requires the
presence of cholesterol in the membrane (31). However, in the case of streptolysin O and
ILY, binding to host cell membranes occurs independently of cholesterol because
membrane binding and pore formation are separate activities (31).
One member of the CDC family, ILY, only lyses human cells as a result of its
domain 4 sequence and this specificity is transferable to other cytolysins (77). The
specificity that ILY displays towards human cells is due to its receptor CD59, which is a
protein that prevents complement deposition on human cell membranes (32). Even
though ILY binds CD59, three loops present in domain 4 of the protein must bind to
cholesterol for the ILY prepore complex to insert into the membrane to form a pore (21,
51, 96).

Cholesterol, the PFO receptor, is necessary and sufficient to trigger

oligomerization and formation of pores by the cytolysin (25, 39, 65). Mutations in the
domain 4 loops of PFO prevent it from binding to cholesterol (97). Additionally, PFO
requires only two residues in loop 1 of domain 4 to bind membrane cholesterol (21).
While the majority of the research on cytolysins have focused on PFO, there is evidence
that streptolysin O forms pores using a similar mechanism (40). Although streptolysin O
requires cholesterol to complete pore formation, the receptor for this cytolysin is
unknown.
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The CDC family member expressed by S. pyogenes, streptolysin O (SLO), is a
571 amino acid protein that has a Sec-dependent signal sequence at its amino terminus,
similar to most other CDC’s. However, unlike most other members of the CDC protein
family, SLO has additional sequence at its amino terminus, known as the N-terminal
extension (48, 58). Within this N-terminal extension, there is a cleavage site for the S.
pyogenes cysteine protease SpeB, which releases 47 amino acids from SLO (76). Both
the uncleaved and cleaved forms of SLO are detectable in the overnight S. pyogenes
culture supernatants and both retain hemolytic activity (18, 76).
Studies conducted with deletion strains demonstrate that cytolysins secreted by
the pathogenic Gram-positive bacteria have an important role during an infection. The
CDC family of proteins can form pores in the plasma membrane of host cells, including
immune cells, in the membranes of organelles, and in the membranes of endocytic
vesicles (22, 33, 44, 46, 57, 78, 87). However, while pore formation is an important
function of these proteins, there is evidence that cytolysins have alternative functions
independent of forming pores (4, 34, 93). Recent work with S. pyogenes demonstrates
that the SLO pore is not required for translocation of the secreted NAD+-glycohydrolase
and that there is specificity in the translocation activity of SLO (55).
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Gram-negative type three secretion system

Trafficking of bacterial toxins into host cells is essential for the virulence of
nearly all pathogenic bacteria (3, 67). The transported toxins can interfere with the host
intracellular signaling pathways to alter the potential response of the host immune system
and to allow the bacteria to proliferate. Many Gram-negative bacteria use specialized
secretion systems, such as the Type III secretion system (T3SS), to direct bacterial toxins
into the host cell cytosol (30, 36). The T3SS specifically delivers bacterial proteins,
known as effectors, into the host cell cytosol using a needle complex called the
injectisome (Figure 8) (27, 61). After the needle complex makes contact with the host
cell membrane, the first effectors released by the T3SS are proteins that form a pore in
the host membrane (61). The needle complex then translocates other effector proteins via
the protected channel from the bacterial cytosol, across the bacterial membranes, through
the pore, and into the host cell cytosol (27).
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Figure 8. The Gram-negative type three secretion system complex. A series of proteins are
secreted by the bacterium to form the needle complex, which traverses the two bacterial
membranes and the periplasm. The needle complex secretes the proteins that make up the pore
(translocase complex) in the host cell membrane. Once this pore forms, chaperones bring other
effector proteins to the T3SS and an ATPase complex supplies the energy for the translocation
process. Adapted from Ref. (27).
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Cytolysin-mediated translocation

The process of cytolysin-mediated translocation (CMT) is the first description of
a Gram-positive bacterium, S. pyogenes, possibly using a system analogous to the T3SS,
to target a secreted protein into the host cell cytosol (Figure 9) (54). This process uses
the cytolysin SLO to translocate the S. pyogenes NAD+-glycohydrolase (SPN) into the
cytosol of the cell host causing cytotoxicity (10, 54).

Figure 9. Original model of cytolysin-mediated translocation in S. pyogenes. The pore
forming protein (SLO) translocates the effector protein (SPN) across the host cell membrane.
Adapted from Ref. (54).

In the S. pyogenes genome, spn and slo are in an operon along with a third gene
named ifs (Figure 10).

Upstream of spn is nusG, which encodes a transcription

antitermination factor (14). Downstream of slo are a series of predicted small open
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reading frames and metB, which encodes a putative cystathionine beta-lyase involved in
amino acid, sulfur, and nitrogen metabolism (2). A promoter present in front of spn
likely controls the expression of the three genes in the operon, however very little is
known about the regulation of these genes (50). Other reports suggest that there is also a
weak promoter in front of slo within the ifs sequence (47, 48, 86). A secretory signal
present at the amino terminus of SPN and SLO permits secretion of the two proteins from
the bacterial cytosol and across the cell wall using the Sec-dependent secretion system
(84). Following secretion from S. pyogenes, SLO directs SPN into the host cell.

Figure 10. The spn operon and the surrounding genes in S. pyogenes. Three proteins
required for CMT are encoded in a single operon. A promoter (represented by an arrow)
upstream of spn is thought to control the expression of spn, ifs, and slo. The flanking genes nusG
and metB genes are not likely involved in CMT. The three predicated open reading frames
downstream of slo do not have any predicted gene assignments and there is no information about
the function of the putative protein products. One gene (SpyM3-0131) is conserved in all
sequenced strains of S. pyogenes.
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Prior to initiating the studies described in Chapters 2, 3 and 4, the following
general characteristics of SPN translocation were known.

In the absence of SLO,

translocation of SPN into the host cell cytosol does not occur (10, 54). Compared to a
wild type S. pyogenes infection, an intraperitoneal infection with a SPN- strain produces
attenuation in disease resulting in a reduction in the mortality of mice (9). Similarly,
deletion of either slo or spn leads to a decrease in host cell cytotoxicity suggesting CMT
is important for pathogenesis (10, 54). In addition, S. pyogenes strains that are unable to
adhere to the host cell due to the absence of M protein also are unable to translocate SPN,
suggesting CMT is a contact dependent process (54). A simple model of CMT predicts
that SPN passively diffuses into the host cell through the 30 nm diameter SLO pore.
However, the observation that streptococci translocate approximately 70% of the total
SPN secreted into eukaryotic cells in vitro indicates that CMT is more complex (10, 54).
Other data demonstrates that a mixed infection with isogenic slo- and spn- mutants is
unable to restore SPN translocation (54). This result indicates that 1) SPN does not
diffuse into the host cell cytosol through the SLO pore, 2) one bacterium must coordinate
the expression and secretion of both proteins, and 3) the localized concentration of SPN
and SLO at the membrane is important for successful CMT. In total, these results lead to
the development of a CMT model in which SPN enters the host cell cytosol through the
SLO pore (Figure 9). The high levels of SPN present in the cytosol suggest that SPN
translocation does not occur via diffusion, but involves a mechanism that permits directed
protein transport into the host cytosol. In addition, since bacterial adherence is necessary
for SPN translocation and the SLO pore is thought to be required, a revised model was
formed that suggested CMT was similar to the Gram-negative T3SS.
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Although it is acknowledged that CMT requires SLO to translocate SPN, the
mechanism of this process is unknown. Unlike other members of the family, SLO has an
N-terminal extension, which does not share sequence homology with other cytolysins
(48, 58). In addition to the SpeB cleavage site, the N-terminal extension appears to
encode a putative protein-protein interaction region (58). Removal of 18 residues that
encode the putative interaction region did not affect CMT suggesting that those residues
did not make any crucial contacts with another protein (58). However, deletion of the
entire N-terminal extension abrogates the ability of SLO to translocate SPN into the
cytosol of eukaryotic cells, but does not affect pore formation (58). PFO is unable to
translocate SPN when expressed from a S. pyogenes SLO- strain, but retains the ability to
form pores (58). The expression of a protein chimera molecule, grafting the N-terminal
extension of SLO onto full length PFO, does not result in SPN translocation although the
chimera is also capable of forming pores (58). Hence, even though the N-terminal
extension of SLO is necessary, it is not sufficient to make a related cytolysin CMTcompetent. Moreover, pore formation alone is not sufficient to allow CMT to proceed.
Overall, these results indicate cytolysin pore formation and translocation can be
uncoupled. The inability of PFO to complement the function of SLO suggests that pores
may not be necessary for CMT. This data also indicates that CMT is not a passive
diffusion process, but is an active process that requires SLO to translocate the majority of
SPN into the host cell cytosol.
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NAD+-glycohydrolase (SPN) effector protein and the specificity of CMT

Currently, SPN is the only described effector protein translocated by CMT. As an
NAD+-glycohydrolase, SPN cleaves β-NAD+ to form two products: nicotinamide and
ADP-ribose (Figure 11) (28).

Although previous studies suggested that SPN also

contains cyclase and ADP-ribosyl transferase activities (45, 99), a recent report
definitively demonstrates that SPN is a strict NAD+-glycohydrolase lacking the two other
enzymatic activities once thought to be associated with the protein (28).

Figure 11. The NAD+-glycohydrolase enzymatic reaction. SPN is a glycohydrolase that
cleaves β-NAD+ to form nicotinamide and ADP ribose. Adapted from Ref. (28).

Several studies show that CMT involves the translocation of SPN into the host
cell cytosol, however, it is not clear if there is a CMT signal sequence present in SPN or
if other secreted S. pyogenes proteins also enter the host cell via CMT. Recent work in
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our lab illustrates that CMT is not a universal process in that it can discriminate between
substrates: SPN and mitogenic factor (another S. pyogenes secreted toxin) (29).
Moreover, any deletions in the primary SPN sequence are intolerable and inhibit CMT
(29). This sequence stringency is not required for the NAD+-glycohydrolase activity, as
deletion of the first 190 residues composing the amino terminus uncoupled translocation
of SPN from its enzymatic activity (29). However, deletions made from the carboxylterminus of SPN prevent both enzymatic activity and translocation (29).

Protein

chimeras expressing increasing amounts of the amino-terminus of SPN in conjunction
with the full sequence of mitogenic factor did not permit translocation of this alternative
substrate (29). The placement of mitogenic factor in the center of the SPN primary
sequence hinders translocation of the protein chimera, but does not affect the NAD+glycohydrolase activity of SPN (29). Mitogenic factor can enter the host cell cytosol
only when placed at the end of the entire primary sequence of SPN (29). This protein
chimera is both CMT-competent and NAD+-glycohydrolase positive.
Overall, these studies indicate that CMT can effectively discriminate between
secreted streptococcal proteins. In addition, the NAD+-glycohydrolase activity of SPN
resides in the carboxyl terminus and deletions in the sequence of SPN uncouple
translocation from the enzyme activity. The amino terminus of SPN may be important
for the polar translocation that occurs during CMT suggesting that the SPN mutants
described in the study have an altered structure that prevents them from interacting with
SLO properly during CMT. Hence, SPN plays an active role in CMT and does not
passively diffuse through the SLO pore.
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Inhibitor of NAD+-glycohydrolase activity in S. pyogenes
Two potential spn alleles naturally exist within the population of S. pyogenes
strains (68, 83). One allele is glycohydrolase positive and the operon encodes ifs, which
produces the immunity factor for SPN (IFS) (59). The second allele is glycohydrolase
negative and the operon contains many nonsense mutations in ifs, which no longer
produces a functional protein. The IFS protein competes with β-NAD+ and inhibits the
glycohydrolase activity of SPN (49, 59). Without IFS, streptococcal cells are susceptible
to the toxic effects of glycohydrolase positive SPN suggesting that some amount of
protein may fold in the bacterial cytosol (59).
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Chapter II

Streptococcus pyogenes cytolysin-mediated translocation
does not require streptolysin O pore formation
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SUMMARY

Bacterial toxin injection into the host cell is required for the virulence of
numerous

pathogenic

bacteria.

Cytolysin-mediated

translocation

(CMT)

of

Streptococcus pyogenes uses streptolysin O (SLO) to translocate the S. pyogenes
nicotinamide adenine dinucleotide-glycohydrolase (SPN) into the host cell cytosol,
resulting in the death of the host cell. Although SLO is a pore-forming protein, previous
studies have shown that pore formation alone is not sufficient for CMT to occur. Thus,
the role and requirement of the SLO pore remains unclear. In this study, we constructed
various S. pyogenes strains expressing altered forms of SLO to assess the importance of
pore formation. We observed that SLO mutants that are unable to form pores retain the
ability to translocate SPN. In addition, SPN translocation occurs after inhibition of actin
polymerization, suggesting that CMT occurs independently of clathrin-mediated
endocytosis. Moreover, despite the ability of mutants to translocate SPN, their cytotoxic
effect requires SLO pore formation.

Modified from Magassa et al. (2010) EMBO Reports
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INTRODUCTION

Secretion and trafficking of bacterial toxins into host cells is essential for the
virulence of nearly all pathogenic bacteria (1, 24). Cytolysin-mediated translocation
(CMT) in Streptococcus pyogenes — an organism that causes a wide range of
complications, including mild diseases (such as pharyngitis and impetigo), lifethreatening invasive diseases (such as necrotizing fasciitis) and post-infectious sequelae
(such as glomerulonephritis and rheumatic fever) — uses the multimeric pore-forming
cytolysin streptolysin O (SLO) to translocate the S. pyogenes nicotinamide adenine
dinucleotide (NAD+)-glycohydrolase (SPN) across the host cell membrane (4, 20). S.
pyogenes NAD+-glycohydrolase cleaves β-NAD+ to produce nicotinamide and ADPribose, and it can also perform cyclase and ADP ribosyl transferase reactions (18, 31).
Although the mechanism of translocation is unknown, deletion of either slo or spn leads
to both decreased cytotoxicity and virulence suggesting CMT is important for
pathogenesis (3, 4, 20).
A simple model predicts that translocation of SPN into the host cell occurs by
diffusion through the 30 nm SLO pore. However, several observations suggest that the
process is more complex, including that co-infection with isogenic slo and spn mutants is
unable to restore CMT (20), that the related cytolysin perfringolysin O (PFO) cannot
complement an SLO- mutant (23), and that CMT can discriminate between SPN and
other streptococcal proteins (10). Furthermore, deletion of specific amino acid residues
in SPN and SLO renders each of them incompetent for CMT, without altering their other
functions (NADase activity and pore formation, respectively) (10, 23). Altogether, the
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data indicate that both SPN and SLO play an active role in CMT and that SPN does not
passively diffuse through the SLO pore.
The ability to uncouple SLO pore formation from CMT indicates that the
presence of pores is not sufficient for SPN translocation. This raises the question as to
whether pore formation is even necessary for CMT. The SLO and PFO proteins are
members of the cholesterol-dependent cytolysin (CDC) family, found in several
pathogenic Gram-positive bacterial species. The three-dimensional structure of PFO and
several other CDCs reveals that these proteins have an analogous domain structure and
use a similar mechanism to form pores (33). The bacterium secretes soluble cytolysin
monomers and pore formation begins when the monomers bind to the host cell membrane
through domain 4 of the protein. The monomers then associate to form an oligomeric
structure, known as the prepore complex, which is bound to the cell surface but does not
insert into the host cell membrane. Finally, conformational changes in domain 3 of each
monomer convert a pair of three alpha-helical bundles into two transmembrane-βhairpins.

This transformation leads to insertion of the prepore complex into the

membrane to form a functional pore with a lumen ranging from 30 nm to 50 nm in
diameter (33). The mechanism of pore formation has been studied extensively in PFO.
Specific mutations in domain 3 lock the protein at different stages of pore formation (33).
In this study, we generated an analogous set of locked SLO mutants and used these to
assess the necessity of the SLO pore in CMT.
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RESULTS

SLO mutants locked at various stages of oligomerization: On the basis of studies using
PFO, the substitution of two conserved adjacent glycine residues located in domain 3 of
SLO (monomer-locked, Table 1), with two valine residues, was predicted to inhibit the
interactions that lead to oligomerization of subunits (33). The substitution of a conserved
domain 3 tyrosine residue with alanine (prepore-locked, Table 1) was predicted to allow
monomers to bind and form an oligomeric structure on the host cell membrane but
prevent insertion of the pore (33). To verify oligomerization phenotypes, the mutant
SLO proteins were expressed with a 6X histidine linker at their carboxy-termini and
purified from Escherichia coli (Figure 1).

Figure 1:

Purified SLO protein variants visualized on a gel stained with Coomassie

brilliant blue. The (A) WT SLO, (B) prepore-locked SLO, and (C) monomer-locked SLO
proteins were expressed with a C-terminal 6X histidine tag, purified using metal ion affinity
chromatography, subjected to SDS-PAGE using a 10% gel, and stained with Coomassie brilliant
blue for visualization.

The image shown is representative of data obtained from three

independent experiments. SLO, streptolysin O; wt, wild type.
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Table 1. Bacterial stains used in this study.
Strains

Relevant genotype/Description/Comments a

Reference

JRS4

wild type/WT

(28)

SLO6

sloΔ113-447/SLO-

(27)

SLO deficient mutant
SPN1

spnΔ177-319/SPN-

(20)

SPN deficient mutant
NGM1

sloY255A/prepore-locked

This study

Expresses prepore-locked SLO
NGM2

sloG398V/G399V/monomer-locked

This study

Expresses monomer-locked SLO
SLOΔ37-102

(23)

sloΔ37-102/SLOΔNT
Expresses SLO lacking an N-terminal translocation domain

NGM3

This study

sloΔ37-102,Y255A/PreporeΔNT
Expresses prepore-locked SLO lacking an N-terminal translocation domain

a

Allelic replacement was used to substitute the endogenous allele in WT JRS4 with the

mutant alleles.
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The soluble purified proteins were incubated in the presence of a cholesterol and
phospholipid mixture mimicking biological membranes and examined by negative-stain
electron microscopy. As expected, WT SLO formed oligomeric ring structures in the
presence of the membrane constituents (Figure 3A). The prepore-locked SLO was able
to form ring structures similar to WT, but these structures were not observed when the
monomer-locked protein was incubated with the lipid mixture (Figure 3A). To confirm
functional phenotypes, Western blot analysis showed that the WT, prepore-locked and
monomer-locked SLO proteins were stable and expressed at equivalent levels (Figure 2).

Figure 2: WT, prepore, and monomer-locked SLO proteins are stable and expressed. Cellfree overnight S. pyogenes culture supernatant from the (A) WT, (B) prepore-locked, and (C)
monomer-locked strains were precipitated on ice with 10% trichloroacetate, subjected to
centrifugation, washed with acetone, and analyzed by a Western blot using anti-SLO antiserum to
visualize the various SLO proteins (23). The image shown is representative of data obtained from
three independent experiments. SLO, streptolysin O; wt, wild type.
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As expected, treatment of A549 lung carcinoma cells with cell-free overnight-culture
supernatants from a strain expressing WT SLO resulted in the release of lactate
dehydrogenase (LDH). By contrast, treatment with supernatants from strains expressing
prepore- and monomer-locked SLO promoted minimal LDH release, which was
indistinguishable from that produced by an SLO- mutant (Figure 3B). Furthermore,
unlike wild-type SLO, prepore- and monomer-locked SLO could not promote detectable
lysis of erythrocytes at either neutral or acidic pH (Figure 3B). These data confirm that
the mutant SLO proteins are not capable of forming a functional pore.

SLO mutants are associated with cell membranes: The process of oligomerization and
pore formation requires cytolysins to bind to the host cell membrane. After an infection
with the WT and mutant strains, A549 cells were fractionated with Triton X-100.
Western blot analysis illustrated that WT SLO localized to the Triton X-100 insoluble
membrane fraction (Figure 3C). Prepore-locked and monomer-locked SLO proteins also
localized to the A549 cell membrane fraction and were present in amounts similar to WT
SLO (Figure 3C). None of these proteins were detected in the Triton X-100 soluble
fraction (not shown). These results indicate that even though mutant SLO proteins were
unable to form pores, both bound membrane as efficiently as WT SLO.
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Figure 3. Prepore- and monomer-locked mutants of streptolysin O localize to host cell
membranes but cannot form pores. (A) Negative-stain electron microscopy was used to
visualize the ability of the purified SLO mutant proteins to oligomerize in the presence of
cholesterol and phospholipids.

The images shown are representative of data from three

independent experiments. Scale bars, 50 nm. (B) The pore-forming ability of the indicated SLO
proteins was assessed by hemolytic activity at pH 7.0 and 6.5 (titers shown) and by the release of
LDH from A549 cells (compared with the total LDH released from lysed cells – control, shown
above). A ‘0’ indicates that no lysis was detected with undiluted supernatant. Data represent
mean±s.e.m. values derived from three independent experiments. (C) After infection for 3.75
hrs, A549 cells were subjected to fractionation with Triton X-100. A Western blot analysis of the
insoluble fraction compared with a precipitate prepared from an overnight culture supernatant
(control) is shown. The image shown is representative of data obtained from three independent
experiments. LDH, lactate dehydrogenase; SLO, streptolysin O; wt, wild type.
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Pore formation is not required for CMT: To assess the requirement for pore formation
in CMT, the prepore and monomer-locked strains were used to infect A549 cells. The
efficiency of SPN translocation was evaluated according to the percentage of the total
SPN expressed, which was translocated into the A549 cell cytosol. Consistent with the
requirement for SLO, the wild-type strain was CMT-competent with most (typically more
than 70%) of the total SPN expressed in the A549 cell cytosolic fraction, whereas the
SLO- mutant was markedly deficient for CMT (typically less than 10%; Figure 4). By
contrast, even though prepore-locked SLO was unable to form pores, the mutant strain
translocated SPN at levels indistinguishable from WT (Figure 4). Although reduced from
that of the prepore-locked strain, the monomer-locked SLO strain was also CMT
competent and translocated SPN at levels significantly higher than the SLO- mutant
(Figure 4; P<0.005). These data indicate that pore formation was not required for CMT
and that, although not essential, SLO oligomerization did improve the efficiency of CMT.
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SLO- Prepore- Monomerlocked
locked

Figure 4. CMT is not dependent on pore formation but is enhanced by oligomerization.
The ability of the SLO pore-forming mutants (Table 1) to translocate SPN into the A549 cell was
analyzed. The bars show the percentage of the total SPN expressed that was translocated into the
A549 cytosolic fraction, after a 3.75 h infection. An ‘*’ indicates that CMT is significantly lower
than wild type (P<0.0001) and ‘**’ indicates CMT is at levels higher than SLO- (P<0.005). The
data represent the mean±s.e.m. values derived from at least three independent experiments.
CMT, cytolysin-mediated translocation; SLO, streptolysin O; SPN, Streptococcus pyogenes
nicotinamide adenine dinucleotide-glycohydrolase; wt, wild type.
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Mutants use a similar CMT pathway: To ascertain whether the same SPN translocation
pathway was used by the WT and prepore-locked strains, we examined the importance of
the SLO amino terminus and sensitivity to cytochalasin D.

A previous study

demonstrated that deletion of 66 residues at the N-terminus of SLO (SLO∆NT) prevented
SPN translocation, but did not affect the ability of the mutant protein to form pores (23).
In addition, inhibitors of actin polymerization known to block the host cell clathrinmediated endocytic pathway (Figure 5) did not prevent WT SLO from conducting CMT
(4, 20).
100

Untreated
CytoD

80

60

40

20

0

37 C

4C

Figure 5: Albumin uptake by A549 cells is inhibited in the presence of cytochalasin D. A549
cells were untreated or treated with 2 μg/mL cytochalasin D at 37ºC or 4ºC. The cells were then
incubated with Alexa-Fluor 594 albumin for 1 hr and uptake measured by counting the total
number of cells stained with the fluorophore. The data represent the mean and the standard
deviation of the mean derived from at least three independent experiments. CytoD, cytochalasin
D.
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A strain was constructed that expressed a prepore-locked SLO that also lacked the Nterminal translocation domain (prepore∆NT, Table 1). As expected, this strain lost the
ability to lyse erythrocytes, a characteristic of both WT and the strain expressing SLO
with only the N-terminal deletion (SLO∆NT, Table 1, Figure 6A). However, prepore∆NT
also lost the competence of WT for CMT (P<0.0001) and was as defective as SLO∆NT
(Figure 6A), demonstrating that the ability of the prepore-locked strain to conduct CMT
is also dependent on the N-terminal domain. Furthermore, similar to WT, the presence of
cytochalasin D did not alter the ability of the prepore-locked strain to conduct CMT
(Figure 6B). Previous studies indicate that at least one CDC has the ability to bind to and
signal via the Toll-like receptor 4 (TLR4) (21, 30). However, a specific TLR4 antagonist
(HTA125, Figure 6D) had no capacity to inhibit CMT by WT or the prepore-locked
strain (Figure 6C). These data show that the CMT pathway promoted by prepore-locked
SLO is indistinguishable from that of WT SLO.
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Figure 6.

The CMT pathway used by the prepore-locked and WT SLO are

indistinguishable. (A) CMT efficiencies of the indicated strains (top) and hemolytic titers
(bottom) were assessed and presented as described for Figure 4. CMT efficiency by the indicated
strains (Table 1) after treatment of A549 cells with (B) cytochalasin D or (C) the TLR4
antagonist HTA125 are shown. Data represent mean±s.e.m. values and an ‘*’ indicates that CMT
is significantly lower than WT (P<0.0001). (D) LPS activation of TLR4 is inhibited in the
presence of the monoclonal antibody HTA125. A549 cells were untreated, treated with 10 μg/mL
of the isotype control IgG2a, or treated with 10 μg/mL of the monoclonal anti-TLR4 antibody
HTA125. The cells were then incubated with LPS for 24 hours and TLR4 stimulation was
measured by the presence of IL-6 in the supernatant. CMT, cytolysin mediated translocation;
SLO, streptolysin O; SPN, Streptococcus pyogenes nicotinamide adenine dinucleotideglycohydrolase; TLR4, Toll-like receptor 4; IL-6, interleukin-6; LPS, lipopolysaccharide; wt,
wild type.
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Pore formation is required for cytotoxicity: To determine whether cytotoxicity requires
both SLO pore formation and SPN translocation, A549 cells were infected with the WT
and mutant strains and membrane integrity assessed by staining with the membraneimpermeable fluorescent probe ethidium homodimer (EthH-1) (20). After 5 hrs, most of
WT-infected A549 could not exclude EthH-1 indicating that their membranes were
compromised (Figure 7). By contrast, infection with the prepore-locked and monomerlocked strains resulted in a more than 90% reduction in numbers of EthH-1-staining cells
compared with WT (P<0.0001). These reduced levels were similar to infection by SLOand SPN- strains (Figure 7).

This reduction in cytotoxicity by the locked mutants

occurred despite the presence of cytosolic SPN.

Although reduced from WT, co-

infection by SPN- (which produces SLO) and prepore-locked strains produced a
significantly higher number of cells with damaged membranes compared to SLO- mutant
alone (Fig. 4, P<0.0001). These data indicate that although SPN translocation occurred
in the absence of an SLO pore, the synergistic SLO/SPN cytotoxic response requires both
the translocation and pore-forming activities of SLO.
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Figure 7. Cytotoxicity requires both SLO pore formation and SPN translocation. The
percentage of A549 cells with cytosolic EthH-1 staining after infection by the indicated strains is
shown (Table 1). An ‘*’ indicates that EthH-1 staining of A549 cells is significantly lower than
wild type (P<0.0001) and ‘**’ indicates that EthH-1 staining is at levels higher than SLO(P<0.0001).

Data represent mean±s.e.m. values derived from at least three independent

experiments. EthH-1, ethidium homodimer 1; SLO, streptolysin O; SPN, Streptococcus pyogenes
nicotinamide adenine dinucleotide-glycohydrolase.
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DISCUSSION

Cytolysin-mediated translocation has been compared previously with specialized
secretion systems, such as the Gram-negative type III secretion system, which inject
effector proteins into the host cell cytosol (8). It has been established that SPN is
translocated through CMT and that SLO is necessary for this process. According to an
early model of CMT, SLO actively translocated SPN into the host cell cytosol through
the lumen of its pore. However, data presented here show that the SLO pore is not
required for SPN translocation.
Although these data do not reveal the pathway for SPN uptake, they do contribute
to a growing appreciation that CDCs possess alternative activities that do not rely on pore
formation. For example, after binding to the membrane, listeriolysin O and pneumolysin
initiate signaling events that result in histone dephosphorylation and deacetylation in the
absence of pores, causing alterations in the host cell gene expression profile (14).
Similarly, pneumolysin can stimulate cytokine secretion and caspase I activation
independently of pore formation (2, 29). Overall, these reports suggest that cytolysins
with dual functionality might be prevalent and that pore formation might be a secondary
activity in certain circumstances.
Pore formation was necessary for cytotoxicity, but the mechanism underlying this
synergistic effect is also unclear. However, it is known that cells have the capacity to
heal SLO pores (15, 34) and it is possible that SPN could interfere with this process.
Cellular wound healing is also a localized process (15), which could explain why a mixed
infection only partly restored cytotoxicity, as the site of SPN delivery and that of pore
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formation would not be coupled efficiently. However, it cannot be ruled out that the
prepore-locked protein exhibited a dominant-negative effect through the formation of
mixed oligomers that resulted in an overall reduction in pore formation.
Given that pore formation is not required for CMT, data presented here suggest a
more active role for the host cell. Streptolysin O is known to bind to cholesterol through
domain 4, thus implicating clathrin-independent endocytosis through lipid rafts (19, 22),
followed by the release of SPN into the host cell cytosol as a possible CMT mechanism.
Several CDCs, including listeriolysin O and PFO, have been shown to localize to
cholesterol-enriched domains of membranes (9, 25), suggesting that SLO also might be
present in similar membrane domains. A recent report argues against this pathway and
indicates that the initial binding of PFO is preferentially to free cholesterol at the
membrane surface, rather than to cholesterol associated with lipid rafts (7).
It is also becoming apparent that CDCs can exhibit marked differences in how
they bind to the membrane, ranging from those that recognize a specific protein to those,
such as PFO, that bind exclusively to cholesterol (33). Interestingly, SLO demonstrates
much less dependence on binding to cholesterol than does PFO (11), suggesting that SLO
might recognize an additional membrane receptor. Thus, a rigorous biophysical
investigation of how SLO binds to the membrane, including determination of whether
CMT is affected by ‘reprogramming’ binding specificity by swapping domain 4 of SLO
with that of other CDCs, probably holds the key to understanding the CMT uptake
pathway.
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MATERIAL AND METHODS

Table 2. Primers used in this study.
Name

Sequence/Description a

NM301p

AAAAAAAACCAAGCGACCGAATCAATG

NM302p

AAAAAATGATTCGGTCGCTTGTGTTCTG
Mutagenesis primers for NGM1

NM32p

AGCTCATTTACAGCTGTCGTTTTAGTAGTAGATGCTGCAGAGCACAATAAGGTGG

NM33p

CCACCTTATTGTGCTCTGCAGCATCTACTACTAAAACGACAGCTGTAAATGAGCT
Mutagenesis primers for NGM2

MAM29

AAAAAAAAACTCTAGAGATTCAGCATTAGCAGTAACAAGG

MAM30

AAAAAAAAAACTCTAGAGAAGAGCGAAGAAGATCACACTGAAG
Mutagenesis primers for NGM3

NM300p

AAAAAAAAACTCGAGGAATGATAAAAAGGTATGAAGG

MAM6

CTGCTCGCATCGATCTACTTATAAGTAATCGAACCA
Primers to amplify slo from pABG5 for insertion into pJRS233

NM46p

AAAAAAACCATGGAATCGAACAAACAAAACACTGCTAGTACAGAAACC

NM66p

AAAAAATCTAGACTAATGATGATGATGATGATGGCCGGCACCCTTATAAGTAATCGAACCATATGG
Primers to amplify slo for insertion into pBAD/gIII

a

Sequence is shown 5’ to 3’. Engineered restriction endonuclease sites are underlined.
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Bacterial strains: Molecular cloning experiments used Escherichia coli TOP10 cells.
The studies with Streptococcus pyogenes utilized the M serotype 6 strain JRS4 (28).
Routine culture of S. pyogenes and E. coli was conducted as previously described (23).
Where appropriate, chloramphenicol or erythromycin was added to media at final
concentrations of 15 μg/ml for E. coli and 3 μg/ml for S. pyogenes or 750 μg/ml for E.
coli and 1 μg/ml for S. pyogenes, respectively.

Manipulation and computational analyses of DNA: Transformation of E. coli and
plasmid DNA isolation were performed as previously described (5). Construction of S.
pyogenes mutants was conducted using standard methods (23). Briefly, each slo mutant
allele (sloY255A, sloG398V/G399V, sloΔ37-102,Y255A) was generated using a pMAM1.4 template
(23) with the primers listed in Table 2 and the product inserted into the vector pABG5
containing a chloramphenicol cassette (13). The mutant alleles were amplified from
pABG5 using the primers in Table 2 and inserted into pJRS233, a temperature-sensitive
vector containing an erythromycin resistance cassette (26). The WT slo allele in JRS4
was substituted with the mutant allele using allelic replacement as previously described
(17).

Restriction endonucleases, ligases, and polymerases were used according to

manufacturer’s recommendations. The fidelity of all DNA sequences created by PCR
was validated by DNA sequencing analyses performed by a commercial vendor
(SeqWright; Galveston, TX).
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Purification of SLO: Mutant and WT slo alleles were expressed in E. coli by using the
pBAD/gIII vector (cat.#V45001, Invitrogen) and were amplified by using the primers
listed in Table 2. The bacteria were grown in Luria Bertani medium containing 100
μg/mL of ampicillin and 0.02% arabinose added to induce expression of recombinant
proteins. The cells were pelleted, resuspended in buffer (20 mM Tris HCl pH 8.0 with
20% sucrose), incubated on ice with lysozyme (15 mg/mL) in the presence of EDTA
(100 mM), and harvested by centrifugation.

Expression constructs contained a C-

terminal 6X histidine tag and were expressed and purified by metal ion affinity
chromatography using commercial matrix (cat.#635503, Clontech). Purity was assessed
by SDS–PAGE and staining with Coomassie brilliant blue R250 (Figure 1).

Analysis of SLO oligomerization: Purified SLO proteins (0.65 μg) were incubated for 1
hr at 25°C in the presence of lipid mixture (0.5 mg/ml) containing about 50 mol%
cholesterol and about 50 mol% 1,2 dioleoyl-sn-glycero-3-phosphocholine (cat.#850375,
Avanti) as described previously (6).

Samples were allowed to absorb onto

formvar/carbon-coated copper grids for 10 min. Grids were washed in dH2O and stained
with 1% aqueous uranyl acetate (Ted Pella, Redding, CA, USA) for 1 min. Excess liquid
was wicked off gently and grids were allowed to air-dry. Samples were viewed on a
JEOL 1200EX transmission electron microscope (JEOL USA, Peabody, MA) at an
accelerating voltage of 80 kV.
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A549 cell fractionation: After infection, A549 cells were lysed using Tris-buffered
saline containing 1% Triton X-100 (cat.#T8787, Sigma), collected by scraping, and
fractions were prepared by ultracentrifugation as described previously (20). Triton-X100-insoluble and -soluble fractions were subjected to sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) using an 8% gel and analyzed by
Western blot analysis using SLO (23).

Analysis of CMT: The S. pyogenes strains used in this study are listed in Table I and
were constructed by standard methods as detailed. Analysis of CMT by using A549 cells
was conducted as described previously (10, 23). Where indicated, cytochalasin D (2
μg/mL, cat.#C2618, Sigma) or the TLR4 antagonist HTA125 (10 μg/mL, cat.#HM2068,
Cell Sciences) were added to media for 30 and 60 min., respectively, before infection by
streptococcal strains.

This cytochalasin D treatment has been shown to inhibit

endocytosis (Figure 5), but not CMT (20).

This HTA125 treatment inhibited

lipopolysaccharide-induced secretion of interleukin-6 (Figure 6D), similar to that
observed elsewhere (35). Data presented represent the mean and the standard error of the
mean derived from at least three independent experiments.

Analysis of cytotoxicity: The integrity of A549 cell membranes after infection was
assessed by the ability to exclude the membrane-impermeable fluorescent probe EthH-1
by using a commercial reagent (Live/Dead, cat.#L3224, Invitrogen) as described
previously (20). The ability to lyse erythrocytes and to promote LDH release was
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analyzed as described previously (20, 23, 27). The data presented represent the mean and
the standard error of the mean derived from at least three independent experiments.

Cytochalasin D treatment of A549 cells: The technique employed to assess the affect
of cytochalasin D on A549 cells was modified from Tagawa et al as described: A549
cells were seeded into 12-well tissue culture plates and grown in the presence of cell
culture medium (DMEM, 50 mM HEPES, 8 mM L-glutamine, and 10% fetal bovine
serum). Confluent A549 cells were washed with and kept in the presence of serum-free
cell culture medium. The cells were then treated for 30 minutes with cytochalasin D
(cat.#C2618, Sigma) at a final concentration of 2 μg/mL at 37ºC or 4ºC. Following the
pretreatment, the cells were incubated with Alexa-Fluor 594 albumin (cat.#A13101,
Invitrogen) for 1 hr at 37ºC or 4ºC. Samples were visualized on a Leica DMIRE2
inverted microscope. Uptake was measured by counting the total number of cells stained
with the fluorophore. The data represent the mean and the standard deviation of the mean
derived from at least three independent experiments. Cytochalasin D inhibits the uptake
of albumin by A549 cells similar to prior observations (16, 32) (Figure 5).

Blocking TLR4 activation: The method used to block TLR4 activation was adapted
from Xie et al as follows – A549 cells were seeded into 6-well tissue culture plates and
grown in the presence of cell culture medium (DMEM, 50 mM HEPES, 8 mM Lglutamine, and 10% fetal bovine serum). Confluent A549 cells were washed with and
kept in the presence of serum-free cell culture medium for 24 hours. The A549 cells
were then treated with 10 μg/mL of the monoclonal anti-TLR4 antibody HTA125
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(cat.#HM2068, Cell Sciences), 10 μg/mL of the isotype control IgG2a (cat.#16-4724-85,
eBiosciences), or untreated for 1 hour at 37°C. Following the 1 hour incubation, the cells
were not stimulated or stimulated with 50 µg/mL LPS (cat.#L5418, Sigma) in the
presence of serum-free medium for 24 hours. The cell supernatants were collected,
subjected to centrifugation at 14,000 rpm for 10 minutes, and stored at -80°C for analysis
of IL-6 using a sensitive ELISA (cat.#HS600B, R&D Systems). The data presented
represent the mean and the standard deviation of the mean derived from at least two
independent experiments.

TLR4 induces the secretion of IL-6 by A549 cells after

stimulation by LPS (Figure 6D).

However, in the presence of HTA125, TLR4 is

inhibited as demonstrated by low levels of IL-6 secretion to levels consistent with
previous observations (35) (Figure 6D).

Statistical Analysis:

Any differences in the mean values of CMT translocation

efficiencies or A549 cell cytotoxicity compared between various mutant and WT strains
were tested for significance by the unpaired t-test (12) and P-values less than 0.05 were
considered significant.
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SUMMARY

The discovery of several complex and intricate specialized secretion systems for
both Gram-negative and positive bacteria suggest translocation of effector proteins into
host cells is an important component of microbial pathogenesis. In the process known as
cytolysin-mediated translocation (CMT), the cholesterol-dependent cytolysin streptolysin
O (SLO) translocates the S. pyogenes NAD+-glycohydrolase (SPN) into the cytosol of a
variety of host cell types including the A549 immortal lung carcinoma cells. However,
the mechanism used to traffic an S. pyogenes effector protein across the host cell
membrane into the cytosol remains obscure.

Recent data demonstrates that in the

absence of a pore, SLO retains the ability to translocate SPN into the host cell cytosol, an
indication that SPN does not travel through the lumen of the SLO pore as previously
suggested. It is currently unknown if a host cell endocytic pathway aids in the process of
translocating approximately 70% of the total secreted SPN. In this study, we assessed the
affects of inhibitors that target host cell endocytosis on CMT.
Inhibition of the clathrin-dependent endocytic pathway using LY294002 does not
affect the ability of SLO to translocate SPN. Furthermore, preliminary data suggests that
using staurosporine to inhibit a kinase involved with caveolae-dependent endocytosis also
does not affect CMT. Surprisingly, a compound that sequesters cholesterol, which is
thought to be important for cytolysin membrane binding, also does not affect CMT. By
contrast, altering the cleavage site of a cysteine protease in the SLO N-terminal extension
abrogates CMT, suggesting that the N-terminal extension primary structure is critical for
SPN translocation. However, a bacterial two-hybrid system based on the restoration of
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Bordetella pertussis adenylate cyclase (CyaA) activity was unable to detect an interaction
between SPN and SLO. In total, while it is still unclear how SPN and SLO interact to
allow for CMT, it remains possible that a host endocytic pathway is actively involved in
SPN translocation.
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INTRODUCTION

Translocation of bacterial effector proteins into the host cell cytosol occurs via an
array of methods. The Type III injectisome machinery of Gram-negative bacteria forms a
pore in the host cell membrane through which effector translocation occurs (15, 17). The
AB5 toxin translocation system of cholera toxin requires the toxin complex to bind to a
receptor in a cholesterol-enriched membrane domain permitting endocytosis, followed by
fusion of the vesicle to the endoplasmic reticulum, and retrograde trafficking of the
effector protein to the host cytosol (7). A specialized secretion system in Streptococcus
pyogenes is known as cytolysin-mediated translocation (CMT) and several studies
provide information about the basic requirements of the process (4, 15, 24, 27).
However, in contrast to the Gram-negative secretion systems described, many details
regarding the mechanism of CMT remain elusive.
Streptolysin O (SLO) is necessary for translocation of the NAD+-glycohydrolase
(SPN) into the host cell cytosol (4, 24, 27). Several models describe the potential
mechanism of CMT. The simplest CMT model predicts that SPN diffuses through the
SLO pore. However, the following observations suggest that CMT is more complex.
The ability of wild type (WT) S. pyogenes to translocate approximately 70% of the total
SPN secreted into the host cell cytosol suggests CMT is likely a directed process that
leads to a polar distribution of SPN (24, 27). Co-infections with isogenic slo- and spnmutants are unable to restore SPN translocation, illustrating that it is unlikely CMT
occurs via SPN diffusion into the host cell (24). Additionally, the related cytolysin,
perfringolysin O (PFO), is unable to translocate SPN, again indicating that passive
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diffusion through the pore is not probable (27). Furthermore, previous work shows that
S. pyogenes strains that are unable to adhere to the host cell membrane are also unable to
translocate SPN, demonstrating that CMT is contact dependent, similar to other
specialized secretion systems such as the Gram-negative Type III system (24).
The previous studies provide data showing that the mechanism of CMT does not
occur by diffusion through the SLO pore. An alternative CMT model involves the
formation of a protected SLO channel that would allow polar translocation of SPN into
the host cell cytosol. This possible CMT mechanism would begin with S. pyogenes
adhering to the host cell membrane, SLO creating a pore in the host membrane, and
forming a protected channel from the bacterial surface to the surface of the host cell.
Once made, the channel would permit SPN to directly enter the host cell. An earlier
study began to test the channel model by determining if the potential SLO channel could
selectively translocate substrates. This study determined that CMT can differentiate
between SPN and mitogenic factor (MF), another S. pyogenes secreted toxin (14).
Furthermore, deletions in the primary SPN sequence are intolerable and inhibit CMT
(14). In addition, use of the SPN secretion signal sequence is not sufficient to make MF a
CMT competent substrate (14). Moreover, a fusion protein encoding the full-length
primary sequence of SPN followed by the MF primary sequence is the only chimera that
permits translocation of MF into the host cell cytosol (14). This suggests the amino
terminus of SPN might be important for polar translocation during CMT and the
carboxyl-terminus is necessary for both translocation and enzymatic activity (14).
Together, the data suggest CMT can distinguish between substrates that would enter the
potential protected SLO channel. These data also indicate that SPN is a substrate that
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actively participates during CMT and that passive diffusion through the SLO pore does
not occur.
Unlike most other members of the cholesterol-dependent cytolysin (CDC) family,
the SLO protein has a 66-residue N-terminal extension, which encodes the cleavage site
for the S. pyogenes cysteine protease (SpeB) at residue 80 (27, 33). One other CDC,
pyolysin from Arcanobacterium pyogenes, has an additional 30 residues at its amino
terminus following the secretion signal (3, 19). Deletion of the first 18 residues of the
SLO N-terminal extension (SLO∆37-54) did not affect CMT suggesting these specific
residues are not necessary (27). However, the SpeB cleavage site is present in the
SLO∆37-54 mutant protein and its requirement for CMT is unclear. Removal of the entire
SLO N-terminal extension (SLO∆37-102) abrogates its ability to translocate SPN indicating
this region is necessary for translocation (27). Although, the N-terminal extension is
necessary for SPN translocation it is not sufficient to convert PFO into a CMT competent
protein (27). When associated with SLO, the N-terminal extension may have a specific
confirmation that can bind to SPN and this extension could form the protected channel.
Previous attempts to detect binding between purified SPN and SLO have been
unsuccessful. The inability to observe protein interactions suggests that the purified
proteins may not have the correct conformation, may not interact efficiently when SLO is
a monomer, or may require an accessory protein.
A recent study illustrates that similar to WT SLO, an SLO mutant protein that
cannot form pores can conduct CMT (25). Hence, the SLO pore is unnecessary for SPN
translocation into the host cell cytosol. This suggests that SPN does not enter the host
cell cytosol through the lumen of a protected channel. Additionally, cytochalasin D
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inhibition of host cell actin polymerization does not affect CMT, suggesting the host cell
clathrin-mediated endocytic pathway is not involved (25). The data from this latest study
significantly alters the model that describes the mechanism of CMT. The current model
now predicts that SLO binds to the membrane and then one of several different host
pathways might be involved in endocytosis of SPN and SLO or SPN alone. Following
endocytosis, the release of SPN from the endocytic vesicle into the cytosol would occur
by an unidentified mechanism.
The work described in the following studies focuses on deciphering whether an
endocytic pathway of the host cell actively participates in CMT.

The cholesterol-

dependent/clathrin-independent endocytic pathway known as CLIC/GEEC, the caveolaedependent pathway, and flotillin-dependent pathway are a few examples of endocytic
pathways that occur independently of clathrin. To begin addressing this question, we
used different pharmacological inhibitors that target proteins involved with host cell
endocytosis.

Although a couple of the inhibitors had no affect on CMT, several

experiments using inhibitors were inconclusive due to difficulties with drug toxicity. In
addition, using a bacterial two-hybrid system we were unable to detect an interaction
between any portion of SPN and SLO. We did discover that mutating the SpeB cleavage
site of SLO inhibits CMT. Thus, cleavage of the SLO N-terminal extension may be
necessary or the mutation in the N-terminal extension prevented a critical binding
interaction required for CMT. The data presented in this chapter has not been submitted
for publication.
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RESULTS

The inhibition of phosphoinositide 3-kinase and protein kinase C do not affect CMT:
The participation of the mammalian host cell during the process of CMT is unclear.
Several studies were conducted inhibiting different steps of the host endocytic process to
determine if the host cell actively participates throughout CMT. After SLO binds to the
host cell membrane, there may be transmission of signals into the cell from the
membrane phospholipids (i.e. phosphatidylinositols).

Phosphatidylinositol (4,5) P2,

(PtdIns (4,5) P2), involved at the start of many signaling cascades, is important for
clathrin-mediated endocytosis (23, 37). Phosphoinositide 3-kinase (PI3-kinase) activity
on PtdIns is required for the formation of PtdIns (4,5) P2 (23, 37). To determine if PI3kinase activity on PtdIns was necessary for CMT, the inhibitor LY294002 was used to
treat A549 cells prior to infection with S. pyogenes. The efficiency of SPN translocation
was evaluated according to the percent of the total SPN expressed that was translocated
into the A549 cell cytosol. Inhibition of PI3-kinase did not affect SPN translocation by
WT S. pyogenes (Figure 1) suggesting lipid phosphorylation was not necessary and
corroborating that CMT did not require clathrin-mediated endocytosis.
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Figure 1: LY294002 inhibition of phosphoinositide 3-kinase does not affect CMT. The level
of SPN translocation by S. pyogenes expressing WT SLO was analyzed in the presence of various
concentrations of LY294002. The bars represent the percent of the total SPN expressed that was
translocated into the A549 cytosolic fraction, after a 3.75 hr infection. The data presented
represent the mean and the standard deviation of the mean derived from at least three independent
experiments.

Clathrin-independent endocytosis typically involves host cell signaling molecules,
which are enriched in cholesterol microdomains. Staurosporine is a naturally occurring
compound that generally inhibits serine/threonine kinases, such as protein kinase C
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(PKC), that phosphorylate proteins required for the process of endocytosis (11, 13). A
preliminary experiment treating A549 cells with various concentrations of staurosporine
prior to infection with WT S. pyogenes was used to assess the role of PKC. Inhibition of
PKC did not prevent SPN translocation (Figure 2), suggesting the caveolae-dependent
pathway may not be necessary.
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Figure 2: Staurosporine inhibition of protein kinase C does not affect CMT. The level of
SPN translocation by S. pyogenes expressing WT SLO was analyzed in the presence of various
concentrations of staurosporine. The bars represent the percent of the total SPN expressed that
was translocated into the A549 cytosolic fraction, after a 3.75 hr infection. The data presented
are from a single experiment.
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Sequestering membrane cholesterol does not affect CMT: Many of the proteins and
lipids involved in clathrin-independent endocytic processes are present in cholesterol
microdomains within the host cell membrane (11). To ascertain the affects of disrupting
the cholesterol microdomains on CMT, various concentrations of nystatin were used to
treat A549 cells before an infection with S. pyogenes. The ability of WT S. pyogenes to
translocate SPN was not affected by cholesterol sequestration (Figure 3). This suggests
that cholesterol does not have to localize to microdomains for CMT to occur, however, it
is unknown if reducing levels of cholesterol in the membrane would have an effect on
CMT.
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Figure 3: Nystatin treatment of membrane cholesterol does not affect CMT. The level of
SPN translocation by S. pyogenes expressing WT SLO was analyzed in the presence of various
concentrations of nystatin. The bars represent the percent of the total SPN expressed that was
translocated into the A549 cytosolic fraction, after a 3.75 hr infection. The data presented
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represent the mean and the standard deviation of the mean derived from at least three independent
experiments.

Inhibitors targeting various stages of host cell endocytosis disrupt SPN secretion by
WT S. pyogenes:

Host cell clathrin-independent endocytosis may require tyrosine

kinases and endosomal trafficking (11). Inhibitors were used to evaluate the role of
tyrosine kinases in CMT. Genistein is a compound, produced by soybeans, that generally
inhibits tyrosine kinases and PP2 is a compound that specifically inhibits the Src family
of tyrosine kinases (1, 2, 10, 16). To evaluate the role of tyrosine kinases in CMT, A549
cells were treated with genistein or PP2 prior to an infection with WT S. pyogenes.
However, numerous attempts to assess the importance of tyrosine kinases were
unsuccessful; there was a large reduction of total SPN secretion from S. pyogenes in the
presence of various concentrations of the tyrosine kinase inhibitors.

Additionally,

experiments treating A549 cells with sodium orthovanadate (tyrosine phosphatase
inhibitor) and chloroquine (inhibitor of endosomal acidification) before an infection with
WT S. pyogenes were also inconclusive due to the overall diminished levels of SPN
secretion in the presence of the inhibitors. Although, these endocytic inhibitors were
used at concentrations that affected SPN secretion, altering the concentrations may permit
their use in future investigations.

Binding between SLO and SPN is undetectable: Although it is not yet clear which
clathrin-independent endocytic pathway may participate in CMT, SPN and SLO
presumably interact during this process. In a previous study, attempts to precipitate and
identify interacting partners from S. pyogenes overnight cell-free culture supernatants
using the SLO antiserum were unsuccessful (26).
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Similarly, incubation of cell-free

culture supernatants with purified SPN, expressing a 6X histidine tag, also did not isolate
a binding partner (26). To investigate further binding between SPN and SLO, we used a
bacterial two-hybrid technique based on the enzymatic activity of the Bordetella pertussis
adenylate cyclase (CyaA) (Table 2). The CyaA enzymatic domain is split into two
fragments, known as T25 and T18, that when brought together permit synthesis of cyclic
adenosine monophosphate (cAMP) in DHP1, a strain of Escherichia coli lacking cyaA
(21).

In cases which the CyaA fragments are fused to proteins that interact, the

production of cAMP allows for expression of maltose metabolism genes (21). Colonies
that express proteins that complement the production of cAMP appear red on
MacConkey/maltose agar plates, an indication that the fused proteins interact (22).
Colonies that appear white or pink on the MacConkey/maltose plates express fused
proteins that do not bring the CyaA fragments together (22).
To determine if SPN and SLO interact through the amino terminus of each
protein, portions of slo and spn were amplified using the primers listed in Table 2 and
each product inserted into a plasmid containing one of the two CyaA fragments. In the
DHP1 E. coli strain, expression of the two CyaA fragments in the absence of interacting
proteins prevented the production of cAMP and pale colonies grew on the plates (T25
and T18C, Figure 4). In contrast, the expression of a leucine zipper domain (control)
brought the two CyaA fragments together in DHP1 and red colonies appeared indicating
that cAMP production occurred allowing maltose utilization (T25-zip and T18C-zip,
Figure 4). Unlike the leucine zipper domain (control), expression of the SLO N-terminal
sequence and the SPN amino-terminus did not bring the two CyaA fragments together
and the colonies were pale in color (Figure 4).
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Table 1. Bacterial two-hybrid plasmids.
Plasmid

Relevant genotype/Description

Reference

pKT25

cya1 – 224/Expression vector encoding T25 fragment of CyaA

(21)

pUT18C

cya225 – 399/Expression vector encoding T18 fragment of CyaA

(21)

pKT25-zip

cya1 – 224-zip/T25 CyaA fragments fused to leucine zipper region of

(21)

a yeast protein
pUT18C-zip

cya225 – 339-zip/T18 CyaA fragments fused to leucine zipper region

(21)

of a yeast protein
pKT25-SLO

cya1 – 224-slo37 – 102/T25 CyaA fragments fused to SLO N-terminal

N-terminal extension

extension

pUT18C-SPN

cya225 – 339-spn41 – 165/T18 CyaA fragments fused to SPN amino

amino-terminus

terminus

pKT25-IFS

cya1 – 224-ifs/T25 CyaA fragments fused to full length IFS

This study

pUT18C-SPN

cya225 – 399-spn/T18 CyaA fragments fused to full length SPN

This study

pKT25-SPN

cya1 – 224-spn/T25 CyaA fragments fused to full length SPN

This study

pUT18C-SLO

cya225 – 399-slo/T18 CyaA fragments fused to full length SLO

This study

pKT25-SLO

cya1 – 224-slo/T25 CyaA fragments fused to full length SLO

This study

pUT18C-SPN

cya225 – 399-spn/T18 CyaA fragments fused to full length SPN

This study

pUT18C-SpyM3-0131

cya225 – 399-orf 0131/T18 CyaA fragments fused to predicated

This study

predicated open reading

This study

This study

SpyM3-0131 open reading frame

frame
pKT25-SpyM3-0131
predicated open reading

cya1 – 225-orf 0131/T25 CyaA fragments fused to predicated
SpyM3-0131 open reading frame

frame
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This study

Figure 4: Interaction between the SLO N-terminal extension and the SPN amino-terminus
is undetectable. DHP1 E. coli expressing the two fragments of the adenylate cyclase (CyaA) in
the presence or absence of interacting proteins were screened on MacConkey-maltose agar plates.
Red colonies indicate a protein-protein interaction that brings the CyaA fragments together.
White or pink colored colonies appear when the CyaA fragments are unable to interact. The
images shown are representative of data obtained from a single experiment. The plasmids used to
express the proteins are listed in Table 1.

To ensure that the CyaA bacterial two-hybrid system could detect S. pyogenes
proteins binding to each other, the nucleotide sequence encoding full length IFS protein
and the nucleotide sequence encoding full length SPN protein were expressed in the
DHP1 E. coli strain (Table 1 and 2). Similar to the leucine zipper domain, IFS and SPN
were able to interact and brought the two CyaA fragments together to produce red
colonies on plates (Figure 5). As expected, the colonies that grew were pale when the
CyaA fragments were expressed alone (Figure 5). To determine if SPN and SLO could
bind to each in the bacterial two-hybrid system, slo and spn were amplified using the
primers listed in Table 2 and each product inserted into a plasmid containing one of the
two CyaA fragments. Attaching SPN to the first CyaA fragment (T25-SPN) and SLO to
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the second CyaA fragment (T18C-SLO) did not restore cAMP production resulting in
pale DHP1 E. coli colonies (Figure 5A). Moreover, swapping the CyaA fragment fused
to SPN (T18C-SPN) and SLO (T25-SLO) produced pale colonies, indicating that CyaA
activity was not complemented (Figure 5B). Thus, the bacterial two-hybrid was unable
to detect binding between SPN and SLO.

Figure 5: SLO and SPN protein interaction is undetectable in the bacterial two-hybrid
system. The ability of SPN and SLO bind to each other and restore CyaA production of cAMP
was assessed by fusing each protein to a CyaA fragment. The bacterial two-hybrid data are
presented as explained in the legend of Figure 4. MacConkey agar plates were used to visualize
binding between S. pyogenes proteins. (A) The first CyaA fragment was fused to SPN and the
second CyaA fragment was fused to SLO. (B) The first CyaA fragment was expressed with SLO
and the second CyaA fragment was expressed with SPN. The images shown are representative of
data obtained from a single experiment. The plasmids used to express the proteins are listed in
Table 1.

However, other S. pyogenes proteins might be necessary for SPN and SLO
binding to occur. There are several small open reading frames downstream of SLO. One
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of these putative genes is present in the same chromosomal location in several S.
pyogenes strains suggesting it might encode a functional protein. The putative protein
encoded by this gene was expressed in the bacterial two-hybrid system to determine if it
could bind to portions of SLO or SPN. Co-expression of the putative protein SpyM30131with the SLO N-terminal extension (Figure 6A) or with full length SPN (Figure 6B)
did not reconstitute the activity of CyaA and lead to the growth of pale colonies. This
suggests that these proteins are unable to bind in this system.

Figure 6:

Binding of a putative S. pyogenes protein SpyM3-0131 to SLO or SPN is

undetectable. The ability of SLO and SPN to bind to the predicated SpyM3-0131 protein in the
bacterial two-hybrid system was assessed. Colonies that expressed the predicated protein with
(A) the SLO N-terminal extension or with (B) full length SPN were pale in color on the
MacConkey agar plates indicating that CyaA activity was not restored. The images shown are
representative of data obtained from a single experiment. The plasmids used to express the
proteins are listed in Table 1.

95

Mutation of the SpeB cleavage site in the N-terminal extension inhibits CMT: SpeB is
a cysteine protease and its predicated recognition and cleavage site within the SLO Nterminal extension is MIKLA (28, 33). The molecular weight of full length SLO is
approximately 61 kD and the cleaved form is approximately 50 kD (33). The high
molecular weight form is the predominant species present in overnight S. pyogenes
cultures that have grown in the presence of the cysteine protease inhibitor E64.
To assess the requirement for SpeB cleavage in CMT, the cleavage site sequence
was changed from MIKLA to MGTLA. The strain expressing the SLOMGTLA protein was
used to infect A549 cells. The efficiency of SPN translocation was evaluated according
to the percent of the total SPN expressed that was translocated into the A549 cell cytosol.
As expected, the WT stain was CMT-competent, whereas the SLO- mutant was unable to
translocate SPN (Figure 7). Surprisingly, the strain expressing SLOMGTLA mutant protein
was CMT incompetent similar to the SLO- mutant (Figure 6). The mutant strain’s
inability to translocate SPN suggests that SpeB cleavage is necessary. However, the loss
of CMT competence may be a result of structural changes in the SLO N-terminal
extension caused by the mutation.
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Figure 7: The SpeB cleavage site is required for SPN translocation. The ability of
the SLO N-terminal extension mutant to translocate SPN into the A549 cell was
analyzed. The bars represent the percent of the total SPN expressed that was translocated
into the A549 cytosolic fraction, after a 3.75 hr infection. The data presented represent
the mean and the standard deviation of the mean derived from at least three independent
experiments.
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DISCUSSION

The studies detailed in this chapter were conducted to begin elucidating the SLOmediated mechanism of SPN translocation.

The recent discovery that pore-forming

mutants of SLO retain the ability to translocate SPN suggests that the host cell is an
active participant during CMT and that some form of endocytosis might be involved. We
used various pharmacological inhibitors to begin assessing the role of the host cell during
CMT.

Previous reports indicate that treating host cells with inhibitors of actin

polymerization do not affect CMT (4, 24). Clathrin-dependent endocytosis depends on
both actin polymerization and the presence of PtdIns(4,5)P2 in the host membrane (6).
We further investigated the importance of this pathway in CMT using an inhibitor to PI3kinase. Data presented here demonstrates that intracellular signaling through PI3-kinase
phosphorylation of lipids is not required for CMT (Figure 1).

However, control

experiments assessing the ability of LY294002 to inhibit PI3-kinase in A549 cells need to
be done. Together, the data from the previous actin polymerization and the current PI3kinase studies suggest that the host cell clathrin-dependent pathway of endocytosis is not
necessary for SPN translocation.
There

are

several

clathrin-independent

endocytosis

pathways

pharmacological inhibitors can target specific stages of the mechanisms.

and

Caveolae-

dependent pathway is an example of a clathrin-independent endocytosis. PKC activity
has been implicated in the caveolae-dependent pathway. Preliminary experiments with
the serine/threonine kinase inhibitor, staurosporine, suggest that PKC activity is not
necessary for CMT (Figure 2). However, this experiment should be replicated to confirm
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this result and control experiments must be done to determine if staurosporine effectively
inhibits PKC.
A common characteristic of clathrin-independent endocytosis is the requirement
for cholesterol microdomains (11). The ability of CMT to occur in the presence of
nystatin, an inhibitor that sequesters cholesterol, suggests that cholesterol does not have
to be in microdomains. However, based on this study the requirement for cholesterol
cannot be eliminated. Additional experiments using an inhibitor that extracts cholesterol,
methyl-β-cyclodextrin, or using SLO mutants that cannot bind to cholesterol will be
necessary to address definitively the requirement of cholesterol in CMT.
Attempts to inhibit other steps of clathrin-independent endocytosis were
unsuccessful. A concentration range of 100 μM to 400 μM of genistein, a general
tyrosine kinase inhibitor, prevents S. pyogenes SPN secretion during an infection as the
drug concentration increases. A caveat to these experiments is that genistein inhibits the
growth of Staphylococcus aureus and other bacteria (18, 40). However, previous studies
used the listed range of genistein concentrations to investigate host cell internalization of
S. pyogenes and host cell signaling in the presence of S. pyogenes (30, 31, 34). One study
reported that concentrations higher than 250 μM affect S. pyogenes viability (34);
however, none of the studies using genistein assessed the affects of the inhibitor on
protein secretion.

Genistein has an apparent half maximal inhibitory concentration

(IC50) of 2.6 μM against some tyrosine kinases (9). Other studies have successfully used
genistein concentrations of 30 μM and 60 μM to inhibit tyrosine kinase activity,
suggesting that genistein has a high potency (12, 41). Therefore, future studies should
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use lower concentrations to avoid any deleterious effects on bacterial growth and protein
secretion.
Efforts to assess if PP2, a specific inhibitor of the Src family of tyrosine kinases,
affect CMT were also inconclusive. Prior to an infection, cells were treated with a PP2
concentration range of 5 μM to 15 μM. All concentrations of PP2 in this range inhibited
SPN secretion by S. pyogenes. However, the concentrations tested may have been too
high, as the IC50 for PP2 is as low as 4 nM for some members of this tyrosine kinase
family and as high as 100 nM for other members (16). Similar affects on S. pyogenes
SPN secretion were observed when sodium orthovanadate and chloroquine were used to
pretreat host cells. An increase in the concentration of sodium orthovanadate, a general
inhibitor of tyrosine phosphatases, ranging from 10 μM to 100 μM coincides with
decreasing amount of SPN secretion during the infection. Chloroquine, makes the pH
environment of endocytic vesicles more basic, to affect vesicle trafficking and fusion
with the lysosome (39). However, there are reports that chloroquine has antibacterial
activity and has the ability to affect DNA and protein synthesis (8, 29, 35).

The

chloroquine studies with S. pyogenes and A549 cells used between 100 μM to 300 μM
concentration, which appear to effect protein secretion.

Overall, the various

pharmacological inhibitors appear to inhibit S. pyogenes SPN secretion. Alternative
compounds such as okadaic acid and calyculin A, both which inhibit serine/threonine
phosphatases, and bafilomycin A, which increases pH of endosomes, can be used in the
future to assess the effect on CMT. SPN translocation by SLO may use a retrograde
trafficking mechanism similar to the AB5 toxin family of proteins. Compounds such as
brefeldin A and golgicide A (36) could be used to reveal the role of retrograde
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trafficking. Future experiments using the previously tested inhibitors should use lower
concentrations of the reagents. Experiments should also assess SPN secretion in the
presence of the prospective and previously tested compounds, which provided
inconclusive data.
Previous experimental efforts did not detect binding between SPN and SLO using
purified proteins in a column pull-down assay (26).

The current attempts using a

bacterial two-hybrid system, based on restoring the activity of CyaA from B. pertussis,
were also unsuccessful.

The bacterial two-hybrid system did detect an interaction

between SPN and IFS, suggesting that it is useful to probe for binding between S.
pyogenes proteins. However, there was no detection of a binding interaction between the
amino-terminus of SPN and the SLO N-terminal extension or between full length SPN
and full length SLO. It is possible that SPN only interacts with SLO when it is an
oligomer. However, the ability of a monomer-locked form of SLO to translocate SPN
suggests that oligomerization might not be necessary for these two proteins to interact
(25). An accessory molecule, such a host protein, might be important for these two to
bind. This accessory protein presumably would bind to both SPN and SLO. The protein
product of a small putative gene downstream of SLO was tested for its ability to bind to
SLO and SPN. This protein was unable to interact with SLO or SPN in the bacterial twohybrid. Nevertheless, there might be an accessory protein important for binding to occur
between SPN and SLO.
Mutation of the SpeB cleavage site significantly decreases CMT, suggesting that
cleavage of SLO must occur or that changes in the sequence prevent the amino-terminus
from possibly binding to its partner. Future experiments to elucidate the role of this site
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in the N-terminal extension could include using the cysteine protease inhibitor E64
during an infection. In addition, two S. pyogenes strains have been made that could be
used to assess the role of the SpeB cleavage site in CMT. The first strain expresses a
point mutation in the SpeB active site (C192S) and the second strain has a deletion of the
first 40 residues of N-terminal extension (SLO∆37-77). Using these strains to infect host
cells will help elucidate the role of the SpeB cleavage site in SLO.
Taken together, the various studies discussed in this section further characterize
the mechanism of SPN translocation. Future work will entail ascertaining 1) the role of
the SpeB cleavage site, 2) which host cell endocytic pathways might be necessary, and 3)
determining how SLO binds to SPN.
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MATERIAL AND METHODS

Table 2. Primers used in this study.
Name

Sequence/Description a

pKT25-SLO Fwd

AAAAAAAATCTAGAGGAATCGAACAAACAAAACACTGC

pKT25-SLO Rev

AAAAAAAGGTACCCGTTACTTTTTTTTGTCTTCTGACTTTTTTTC
Primers to amplify the slo N-terminal extension from pABG5 for insertion into pKT25
(pKT25-SLO N-terminal extension)

pUT18C-SPN Fwd
pUT18C-SPN Rev

AAAAAAAACTGCAGGGTTAGTGGCAAAGAAAACAAAAAAAG
AAAAAAAGGATCCTATTTATCAATCTCAATGTGATGCGG
Primer to amplify the spn amino-terminus domain from pJOY7 (pABG5-spn-ifs) for insertion into
pUT18C (pU18C- SPN amino-terminus)

pKT25-SLO Fwd

AAAAAAAATCTAGAGGAATCGAACAAACAAAACACTGC

NM024p

AAAAAAAGGTACCCGTTACTTATAAGTAATCGAACCATATGGGC
Primers to amplify slo from pABG5 for insertion into pKT25 (pKT25-SLO)

pUT18C-SPN Fwd

AAAAAAAACTGCAGGGTTAGTGGCAAAGAAAACAAAAAAAG

pUT18C-SPN Rev 2

AAAAAAAGGATCCTACTTCCTATCTTGCATTCTATCTTGCATTTTC
Primers to amplify spnG330D from pJOY44 (pABG5-spn-ifs) for insertion into pUT18C (pUT18C-SPN)

NM008p

AAAAAAAAGGATCCCGTTAGTGGCAAAGAAAACAAAAAAAG

NM009p

AAAAAAAAAAGGTACCCGTTACTTCCTATCTTGCATTCTATCTTGCATTTTC
Primers to amplify spnG330D from pJOY44 (pABG5-spn-ifs) for insertion into pKT25 (pKT25-SPN)

pKT25-SLO Fwd

AAAAAAAATCTAGAGGAATCGAACAAACAAAACACTGC

NM024p

AAAAAAAGGTACCCGTTACTTATAAGTAATCGAACCATATGGGC
Primers to amplify slo from pABG5 for insertion into pUT18C (pUT18C-SLO)

pKT25-IFS Fwd

AAAAAAAAAGGATCCCATGTATAAGGTGCCAAAGGGTTTAGAAC

pKT25-IFS Rev

AAAAAAAAAGGTACCCGTTAAAATGTTTCTATTGTTCTTTCGACC
Primers to amplify ifs from pJOY7 (pABG5-spn-ifs) for insert into pKT25 (pKT25-IFS)

NM017p

AAAAAAAAGGATCCCAATGAGGCAGTAGCTACTCAAGCATGTGCAGATGGAACAAAT

NM018p

AAAAAAAGGTACCCGTTATTTTGTGACTGTATCCGTAGTAGGCTG
Primers to amplify SpyM3-0131 from JRS4 chromosomal DNA for insertion into pKT25 or pUT18C

a

Sequence is shown 5’ to 3’. Engineered restriction endonuclease sites are underlined.
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Table 2. Primers used in this study continued.
Name

Sequence/Description a

Kpn1 Fwd

AAAAAAGGTACCCTTGCTCCCAAAGAAATGCC

Kpn1 Rev

AAAAAAGGTACCCATATCGTTAGAGTTAAGC
Inverse PCR primers used to make the N-terminal extension mutant SLOMGTLA from pMAM1.4 (27)

NM300p

AAAAAAAAACTCGAGGAATGATAAAAAGGTATGAAGG

MAM6

CTGCTCGCATCGATCTACTTATAAGTAATCGAACCA
Primers to insert the sequence of the N-terminal extension mutant SLOMGTLA into a temperature sensitive
plasmid

a

Sequence is shown 5’ to 3’. Engineered restriction endonuclease sites are underlined.
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Bacterial strains: Molecular cloning experiments used Escherichia coli TOP10 cells.
The studies with Streptococcus pyogenes utilized the M serotype 6 strain JRS4 (38).
Routine culture of S. pyogenes and E. coli was conducted as previously described (27).
Where appropriate, chloramphenicol or erythromycin was added to media at final
concentrations of 15 μg/ml for E. coli and 3 μg/ml for S. pyogenes or 750 μg/ml for E.
coli and 1 μg/ml for S. pyogenes, respectively.

Analysis of CMT: Streptococcal cultures were grown overnight in ThyB at 37°C,
subjected to centrifugation, washed twice with 1X phosphate saline buffer (PBS), and
resuspended in pre-warmed cell culture medium (DMEM with glucose, 8 mM Lglutamine, 50 mM HEPES, and 10% heat inactivated fetal bovine serum) to an OD600 of
0.875 in a Shimaduzu UVmini or to an OD600 of 0.66 in a Beckman Coulter DU730.
Confluent A549 cells were infected with 1 mL of the resuspended streptococcal strains
for 3.75 hrs. After the infection, the culture supernatant was sterilized using a 0.2-micron
filter unit. The A549 cells were washed twice with 1X PBS and lysed with a 1X PBS0.05% saponin solution containing a mini complete protease inhibitor tablet
(cat.#1836153, Roche) at 37°C for 5 minutes.

The cytosolic fractions subjected to

centrifugation at top speed for 10 minutes at 4°C, followed by an ultracentrifugation at
135,380 x g for 1 hr at 4°C. SPN activity in the A549 cytosolic fraction was analyzed as
described earlier (24).

When indicated, LY294002 (10 µM, 50 µM, 100 µM;

cat.#440204, EMD Chemicals), staurosporine (0.5 µM, 1 µM; cat.#569396, EMD
Chemicals), and nystatin (5 µg, 25 µg; cat.#N6261, Sigma Aldrich) were incubated with
the A549 cells at for 1 hr prior to infection. Genistein (cat.#345834, EMD chemicals),
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PP2 (cat.#529576, EMD Chemicals), sodium orthovanadate (cat.#450243, Sigma
Aldrich), and chloroquine (cat.#C6628, Sigma Aldrich) were used to pretreat A549 cells
to assess the effects on CMT.

Manipulation and computational analyses of DNA: Transformation of E. coli and
plasmid DNA isolation were performed as previously described (5). Construction of S.
pyogenes SLOMGTLA mutant was conducted using standard methods (27). An inverse
PCR was used to generate the slo mutant allele (sloMGTLA) from the pMAM1.4 template
(27) with the primers listed in Table 2. The mutant allele was amplified from pABG5
using the primers in Table 2 and inserted into pJRS233, a temperature-sensitive vector
containing an erythromycin resistance cassette (32). The WT slo allele in JRS4 was
substituted with the mutant allele using allelic replacement as previously described (20).
Restriction endonucleases, ligases, and polymerases used according to manufacturer’s
recommendations.

DNA sequencing analyses performed by a commercial vendor

(SeqWright; Galveston, TX) validated the fidelity of all DNA sequences created by PCR.

Construction of Bordetella pertussis bacterial two-hybrid fusion plasmids:

The

plasmids pKT25, pUT18C, and pUT18 (multiple cloning site at the amino-terminus)
were obtained from the Vogel Lab courtesy of the Dr. Daniel Ladant (21). Control
plasmids expressing a yeast zipper protein, pKT25-zip and pUT18C-zip, were also
provided (21). Construction of the fusion genes was done using standard methods (27).
The various bacterial two-hybrid plasmids were made using the primers and templates
listed in Table 2. The pKT25 expression vector contained a kanamycin cassette (added to
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media at final concentration of 50 μg/mL) and the pUT18C expression vector contained
an ampicillin cassette (added to media at final concentration of 100 μg/mL) (22). The
restriction

endonucleases,

ligases,

and

polymerases

were used

according

to

manufacturer’s recommendations. Transformation of the TOP10 E. coli and plasmid
DNA isolation were performed as previously described (5). As previously stated, use of
the restriction endonucleases, ligases, and polymerases followed the manufacturer’s
recommendations.

DNA sequencing analyses performed by a commercial vendor

(SeqWright; Galveston, TX) validated the fidelity of all DNA sequences created by PCR.

Analysis of the bacterial two-hybrid fusion plasmids: The cyaA- E. coli strain DHP1
was obtained from Dr. Joseph Vogel’s laboratory courtesy of the Dr. Daniel Ladant (21).
Co-transformation of the DHP1 E. coli with pKT25 and pUT18C derived plasmids was
performed using standard methods (27). Bacteria were grown at 30°C on MacConkey
(cat.#281810, BD Difco) agar plates supplemented with 1% maltose (cat.#216830, BD
Difco) in the presence of kanamycin (50 μg/mL) and ampicillin (100 μg/mL). Following
the

appearance

of

colonies,

individual

colonies

were

restreaked

MacConkey/maltose plates containing both antibiotics and grown at 30°C.
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Chapter IV

Specificity of Streptolysin O Domain 4 in
Cytolysin-Mediated Translocation
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SUMMARY

The process of microbial pathogenesis typically involves secretion of toxic
proteins into host cells. Transport of bacterial effector proteins occurs through various
secretion systems and one common feature is the use of translocator. Cytolysin-mediated
translocation (CMT) of Streptococcus pyogenes uses streptolysin O (SLO) to translocate
the S. pyogenes NAD+-glycohydrolase (SPN) into the host cell cytosol. While SLO is
required for SPN translocation and can perform this activity without forming a pore, the
details regarding the basis of this specificity and the contacts made with the host cell
membrane are unknown.

In the current study, we assessed the requirement and

specificity of SLO domain 4 binding to the host cell membrane. Through a series of
domain 4 swaps between SLO and related cytolysins, we found that although binding is
necessary it is not sufficient for CMT. We show that a SLO/PFO domain 4 chimera is
unable to conduct CMT. However, a specific primary structure of SLO domain 4 can
restore CMT activity to the SLO/PFO domain 4 chimera. Although, reducing the levels
of cholesterol in the membrane do not affect CMT, mutations that interrupt cholesterol
binding indicate the sterol does increase the efficiency of CMT.
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INTRODUCTION

The translocation of toxic effector proteins into the host cell is an important part
of microbial pathogenesis. Trafficking of bacterial toxins generally requires a secretion
system that has a dedicated translocator. Many Gram-negative bacteria direct toxins
across the plasma membrane into the host cell cytosol using specialized secretion
systems, such as the Type III secretion system, which has a needle complex and a
translocator comprised of three proteins (25). Other toxins, like anthrax and diphtheria
toxins, gain access to the cytosol through the endocytic pathway, after the specific
translocator binds to the plasma membrane to allow endocytosis of the translocator-toxin
complex (5, 32, 39).

The Gram-positive bacterium Streptococcus pyogenes uses a

process denoted as cytolysin-mediated translocation (CMT) to transport an effector
protein into the host cell.
During CMT, streptolysin O (SLO) is required for the directed translocation of
the S. pyogenes NAD+-glycohydrolase (SPN) across the host cell membrane into the host
cell cytosol (3, 22, 24). SPN is an enzyme that cleaves β-NAD+ to produce nicotinamide
and ADP-ribose; however, SPN does not possess cyclase or ADP-ribosyl transferase
activities as previously described (8, 20, 36). Both SPN and SLO are part of the large
collection of virulence proteins secreted during an S. pyogenes infection, which can lead
to many types of clinical diseases such as pharyngitis, necrotizing fasciitis, and
glomerulonephritis. Earlier reports indicate that the majority of SPN secreted is present
in the host cytosol, that co-infection with isogenic slo and spn mutants cannot reconstitute
CMT, and that S. pyogenes mutants deficient in either protein are less cytotoxic and less
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virulent (2, 3, 22, 24). Although SLO is necessary for polar translocation of SPN, the
foundation of this specificity remains elusive.
The original CMT model predicts SLO forms a pore in the host cell membrane
and SPN diffuses through the lumen of the pore to enter the host cell cytosol. However,
extensive data suggests the process is more complex. First, SLO has an additional 66
residues at its amino terminus in comparison to related proteins and removal of this
sequence abrogates the ability of SLO to translocate SPN, but does not affect SLO pore
formation (24).

Second, further research illustrates that the related cytolysin

perfringolysin O (PFO) is not CMT-competent when expressed from a SLO- strain of S.
pyogenes, even though it can form pores (24). Third, grafting the SLO N-terminal
extension onto PFO cannot restore SPN translocation (24). Hence, the SLO N-terminal
extension is required but it is insufficient at making a related protein CMT-competent.
Consequently, the inability of the pore-forming PFO protein to translocate SPN creates
uncertainty about the role of pore formation during CMT.
A recent study used two S. pyogenes strains expressing different SLO mutations
to assess the importance of pore formation in CMT. One mutant expresses an SLO
protein locked in a state known as the prepore-complex, in which SLO can form
oligomers on the host cell surface but cannot insert the complex into the host cell
membrane (23). The second mutant expresses an SLO protein locked in the monomer
state and this protein can bind to the host cell surface but is unable to oligomerize (23).
Neither the prepore- nor the monomer-locked SLO proteins are capable of forming pores
in host cells. However, similar to wild type, the prepore-locked strain is CMT-competent
(23). The monomer-locked strain also retains the ability to translocate SPN, though SLO
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oligomerization enhances CMT (23). Additionally, deletion of the N-terminal extension
from the prepore-locked SLO protein abolishes CMT indicating that the pore-forming
mutant and wild type (WT) SLO use an indistinguishable mechanism to translocate SPN
(23). In total, these studies demonstrate that pore formation is unnecessary for CMT
indicating that poration and translocation are two independent SLO activities. The ability
of SLO to translocate SPN in the absence of a pore suggests that the contacts made with
the host cell membrane might be crucial for CMT.
SLO, PFO, and intermedilysin (ILY) are representatives of the cholesteroldependent cytolysin (CDC) family of proteins (15). The CDCs are large oligomeric poreforming proteins expressed and secreted by several species of pathogenic Gram-positive
bacteria (37). These proteins share approximately 40 to 70% amino acid similarity and
previous analysis of resolved crystal structures illustrate that all members of the family
likely have 1) an analogous fold that creates four discontinuous domains and 2) a similar
pore-forming mechanism (1, 12, 28, 30). Domain 4 of the CDCs is the only portion of
the protein to be encoded by a continuous primary structure. Each cytolysin monomer
makes the initial contact with the host cell membrane via domain 4 of the protein (14, 29,
38). This domain contains loops that bind to cholesterol and a tryptophan rich motif
called the undecapeptide (6, 34, 35).
Cholesterol has an important role in the cytolysin-membrane interactions. It is
evident from a number of studies that the membrane receptor for PFO is cholesterol (7,
10, 14, 35). It is also known that pore formation by ILY and SLO requires the presence
of cholesterol in the membrane; specifically the cholesterol binding loops of domain 4
must insert into the membrane to complete the pore formation process (10, 34, 35).
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However, the PFO requirement for cholesterol is not limited to pore formation but
encompasses the ability of PFO to bind to the host cell membrane (16). Unlike PFO, the
receptor for ILY is CD59, a membrane anchored regulatory protein that inhibits a poreforming complex activated by the immune system from attaching to the surface of human
cells (11, 18, 21, 34). The majority of the cytolysins are capable of binding and lysing
cells from many mammalian species. However, the activity of ILY is restricted to human
cells and domain 4 confers this specificity (10, 26-28). The ubiquitous presence of CD59
on human cells also supports the specific action of ILY. Although ILY binds to CD59 to
form the prepore-complex, the cytolysin must also bind to cholesterol because as the
prepore-complex enters the membrane to form a pore the cytolysin disengages from its
receptor CD59 (21).
While the membrane receptor is unknown, SLO can bind to membranes with
reduced levels of cholesterol similar to ILY (10). Specific mutations in the cholesterol
binding loops of domain 4 decrease the ability of SLO to bind to cholesterol (6).
However, the function and importance of contact with cholesterol in the membrane
during CMT is unknown. We explore the role of receptor specificity and membrane
interactions on CMT using domain 4 swaps made between SLO and related cytolysins.
These studies reveal that CMT does depend on domain 4 specificity.

In addition,

reducing membrane cholesterol, to levels that inhibit binding of PFO domain 4, does not
affect CMT. Furthermore, mutating the first cholesterol-binding loop demonstrates that
cholesterol is not necessary but it does enhance CMT.
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RESULTS

Binding to host cell membranes is necessary for SLO to translocate SPN: To ascertain
the role of domain 4 in CMT, an in-frame deletion in slo was generated to create a mutant
protein lacking the domain (SLOΔD4, Table 1).

Western blot analysis showed that

compared to WT, the resulting mutant was secreted, soluble, and stable (Figure 1A).
Following an infection with the WT and SLOΔD4 expressing strains, A549 cells were
fractionated using Triton X-100 and evaluated using a Western blot. WT SLO localized
to the Triton X-100 insoluble cell membrane fraction, however, SLOΔD4 did not localize
to the A549 cell membrane (Figure 1B) indicating this domain was needed to bind to host
cells. In addition, unlike WT SLO, cell-free overnight culture supernatants from the
strain expressing SLOΔD4 did not result in lysis of rabbit erythrocytes (Figure 1C). To
determine the requirement for domain 4 in CMT, the SLOΔD4 strain was used to infect
A549 cells for 3.75 hrs. The efficiency of SPN translocation was assessed according to
the percent of the total SPN expressed that was translocated into the A549 cell cytosol.
As expected, the WT strain was CMT-competent with most (typically >70%) of the total
SPN expressed present in the A549 cell cytosolic fraction (Figure 1C). In contrast,
SLOΔD4 strain was CMT deficient similar to the SLO- strain (Figure 1C). Thus binding to
the host cell membrane is necessary for CMT; however, the question is whether it is
sufficient for SPN translocation to occur.
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Table 1. Bacterial stains used in this study.
Strain

Relevant genotype/Description

Reference

JRS4

wild type; WT

(33)

WT SLO
SLO6

slo113-447; SLO-

(31)

SLO deficient mutant
NGM4

slo466-574; SLO∆D4

This study

SLO lacking the domain 4
NGM5

slo1-463 ily417-532; SLO/ILYD4

This study

SLO domain 1 – 3 sequence and ILY domain 4 sequence
NGM6

slo1-463 ily417-532, G485E, A486C, P493W; SLO/ILYD4-ECW

This study

SLO domain 1 – 3 sequence and ILY domain 4 sequence with typical undecapeptide
NGM7

slo1-463 pfo390-500; SLO/PFOD4

This study

SLO domain 1 – 3 sequence and PFO domain 4 sequence
NGM8

slo1-463 pfo390-500, D469K, S472D, Y474R, P477K, T479S, N480K, N481E; SLO/PFOD4-swap1

This study

SLO domain 1 – 3 sequence and PFO domain 4 sequence with SLO swap 1 sequence
NGM9

slo1-463 pfo390-500, T427R, Q433Y, H438P, E446G; SLO/PFOD4-swap2

This study

SLO domain 1 – 3 sequence and PFO domain 4 sequence with SLO swap 2 sequence
NGM10

slo1-463 pfo390-500 F406Y, V408I, A409L, V413I, S414N, K417D, E418K, N420K, L423I, H425K, K426R, T427R,
G430N, Y432W, Q433Y, D434S, A437S, H438P;

This study

SLO/PFOD4-swap3

SLO domain 1 – 3 sequence and PFO domain 4 sequence with SLO swap 3 sequence
NGM11

sloL565G; SLOL565G

This study

Mutation in cholesterol binding loop
NGM12

sloL565D; SLOL565D

This study

Mutation in cholesterol binding loop
NGM13

slo1-102 pfo48-389 slo464-565; SLONT;D4/PFO

This study

SLO N-terminal extension sequence, PFO sequence, and SLO domain 4 sequence
a

Allelic replacement was used to substitute the endogenous allele in WT JRS4 with the

mutant alleles.
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Figure 1: SLO Domain 4 is important for binding and CMT. (A) Cell-free overnight S.
pyogenes culture supernatant from the WT, SLO-, and SLOΔD4 were precipitated on ice with 10%
trichloroacetate and analyzed by a Western blot using anti-SLO antiserum. (B) Following a 3.75
hr infection with the WT, SLO- and SLOΔD4 strains, A549 cells were subjected to fractionation
using Triton X-100. Shown is a Western blot analysis of the insoluble fraction, along with a
protein precipitate prepared from an overnight culture supernatant (precipitated SLO). The image
shown is representative of data obtained from three independent experiments. (C) The ability of
the SLOΔD4 strain (Table 1) to translocate SPN into the A549 cell (top) and hemolytic titers
(bottom) were analyzed.

The bars show the percent of the total SPN expressed that was

translocated into the A549 cytosolic fraction, after a 3.75-hour infection. An ‘*’ indicates that
CMT is significantly lower than WT (P<0.05). N.D. denotes the limit of detection for hemolytic
activity using an undiluted sample. The data presented represent the mean and the standard
deviation of the mean derived from at least three independent experiments.
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The domain 4 sequence of ILY is unable to restore CMT: An alignment of the domain
4 primary sequence shows SLO and ILY are 34.7% identical and 49.6% similar, while
SLO and PFO are 64.5% identical and 74.5% similar (Figure 2).

SLO
PFO
ILY

(464) SGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSR (524)
(390) KGKINLDHSGAYVAQFEVAWDEVSYDKEGNEVLTHKTWDGNYQDKTAHYSTVIPLEANAR (450)
(417) DGALTLNHDGAFVARFYVYWEELGHDADGYETIRSRSWSGNGYNRGAHYSTTLRFKGNVR (477)
.* :.*.*.**:**:: : *:*:.:* .* *.: : *..* .: : :**.: : .* *

SLO
PFO
ILY

(525) NIRIMARECTGLAWEWWRKVIDERDVKLSKEINVNISGSTLSP-YGSITYK---- (574)
(451) NIRIKARECTGLAWEWWRDVISEYDVPLTNNINVSIWGTTLYP-GSSITYN---- (500)
(478) NIRVKVLGATGLAWEPWRLIYSKNDLPLVPQRNISTWGTTLHPQFEDKVVKDNTD (532)
***: . .****** ** : .: *: * : *:. *:** *
. . :

Figure 2: Domain 4 of SLO is similar to PFO: An amino acid sequence alignment of domain 4
from SLO, PFO, and ILY was generated using the CLUSTALW2 algorithm. An asterisk ‘*’
below the alignment denotes identical amino acids, while ‘.’ and ‘:’ denote similar and highly
similar residues respectively. The dark bar above the SLO sequence indicates the undecapeptide
sequence. The underlined amino acids in ILY sequence indicate the atypical residues present in
the undecapeptide sequence. The dark bars over the PFO sequence indicate the residues changes
in the SLO/PFOD4-swap1 and SLO/PFOD4-swap3 strains, while the dark circles indicate the residues
changes in the SLO/PFOD4-swap2 strain. The box denotes three cholesterol-binding residues, which
are located at the tip of three loops in domain 4 of cytolysins.
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ILY and SLO are similar in their capability to bind to membranes after cholesterol
extraction (10). Recent reports indicate domain 4 of ILY binds to both CD59 and
cholesterol (11, 21). While domain 4 of SLO is required for the process of CMT, it is
unclear if specific interactions with the membrane are necessary.

To address this

question, a chimera expressing the domain 4 sequence from ILY in lieu of the WT SLO
sequence was made to assess the specificity of the region (SLO/ILYD4, Table 1).
Resembling WT SLO, the SLO/ILYD4 protein was localized to the Triton X-100
insoluble cell membrane fraction following an infection (Figure 3A) illustrating that the
protein was expressed and could bind to A549 cell membranes.

As expected, the

SLO/ILYD4 protein present in culture supernatants was unable to lyse rabbit erythrocytes
but retained hemolytic activity against human erythrocytes (Figure 3B).

This data

demonstrated that the SLO/ILYD4 protein gained the innate activity of the ILY domain 4
and suggested that the SLO/ILYD4 chimera protein was likely binding to the native
receptor CD59. An infection with A549 cells was used to determine if the SLO/ILYD4
strain also retained the ability to carry out CMT. Even though membrane binding was
maintained, the strain expressing the SLO/ILYD4 chimera was unable to translocate SPN
into the A549 cell cytosol (Figure 3B).
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Figure 3: SLO/ILYD4 mutant allows membrane binding but is insufficient in conducting
CMT. (A) A Western blot analysis of the Triton X-100 insoluble fractions from A549 cells that
were infected for 3.75 hr with the indicated strains is shown, along with a protein precipitate
prepared from an overnight culture supernatant. The image shown is representative of data
obtained from three independent experiments. (B) The SLO/ILYD4 strain (Table 1) was tested for
CMT efficiency (top) and hemolytic titers (bottom) and the data is presented as described for
Figure 1. An ‘*’ indicates that CMT is significantly lower than WT (P<0.05). N.D. denotes the
limit of detection for hemolytic activity using an undiluted sample. The data presented represent
the mean and the standard deviation of the mean derived from at least three independent
experiments.
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In comparison to other cytolysins, domain 4 of ILY has a variant undecapeptide sequence
with three amino acid differences (26). The undecapeptide is important for stabilizing
cytolysins in the host cell membrane (28, 34). An alternative chimera replacing the three
variant residues in the undecapeptide of the SLO/ILYD4 protein was created to assess if
there would be a gain of CMT function (SLO/ILYD4-ECW, Table 1). The SLO/ILYD4-ECW
protein was present in the Triton X-100 insoluble fractions suggesting it was able to bind
to cell membranes (Figure 4A), but was unable to lyse any erythrocytes (Figure 4B). The
loss of detectable hemolytic activity suggests that the chimera protein might be unable to
bind properly to the membrane. Additional experiments showed that the SLO/ILYD4-ECW
strain was similar to the SLO- strain and translocated significantly less SPN than WT
SLO strain (Figure 4B; P<0.05). Thus, even though the SLO/ILYD4 and SLO/ILYD4-ECW
proteins maintained the ability to bind to A549 cells, it was apparent that solely binding
the membrane was not sufficient for CMT and that swapping the domains abrogated the
ability of SLO to translocate SPN.

129

Figure 4: SLO/ILYD4-ECW mutant does not restore CMT. (A) A Western blot analysis of the
Triton X-100 insoluble fraction along with a precipitate is shown and presented as described for
Figure 1. (B) The SLO/ILYD4-ECW strain (Table 1) was tested for CMT efficiency (top) and
hemolytic titers (bottom) and the data is presented as described for Figure 1. An ‘*’ indicates that
CMT is significantly lower than WT (P<0.05). N.D. denotes the limit of detection for hemolytic
activity using an undiluted sample. The data presented represent the mean and the standard
deviation of the mean derived from at least three independent experiments.
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Despite the level of sequence homology, SLO and PFO binding is not the same: The
large degree of variability (49.6%, Figure 2) between the domain 4 sequence of SLO and
ILY may have affected the ability of the SLO/ILYD4 protein to translocate SPN. Since
SLO and PFO have a higher degree of sequence similarity in the region of domain 4
(74.5%, Figure 2), it was feasible that this sequence could functionally serve as a
replacement. To test this premise, a chimera expressing the domain 4 sequence from
PFO in place of the WT SLO sequence was generated to resolve the specificity of this
region (SLO/PFOD4, Table 1).

Collection of the Triton X-100 insoluble membrane

fractions demonstrated that the SLO/PFOD4 chimera protein localized to this fraction
(Figure 5A). However, extraction of membrane cholesterol using methyl-β-cyclodextrin
(mβc) abolished the SLO/PFOD4 protein localization (Figure 5A) indicating that the
chimera demonstrates the higher dependence on cholesterol characteristic of PFO. In
contrast, WT SLO was located in the Triton X-100 insoluble membrane fraction in the
absence and presence of mβc, though decreasing the levels of cholesterol in the
membrane does reduce SLO binding (Figure 5A). Similar to the activity of PFO, the
SLO/PFOD4 chimera protein in culture supernatants efficiently lysed rabbit erythrocytes
in comparison to WT SLO (Figure 5B). The ability of the SLO/PFOD4 expressing strain
to conduct CMT was assessed through an infection of A549 cells. Similar to the SLOstrain, the SLO/PFOD4 expressing strain is unable to translocate SPN (Figure 5B). Thus,
this suggests that cholesterol might not be directly involved in SPN translocation. In
addition, although the domain 4 sequence of WT SLO and PFO protein have a great
degree of similarity, the PFO domain 4 was unable to replace the function of SLO
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domain 4. The sequence differences might prevent the SLO/PFOD4 chimera protein from
binding to the membrane in an SLO specific manner.
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Figure 5: SLO/PFOD4 mutant is unable to conduct CMT. (A) A549 cells in the absence or
presence of methyl-β-cyclodextrin were infected for 3.75 hrs.

Afterwards, the cells were

subjected to fractionation using Triton X-100. A Western blot analysis is shown and is presented
as described for Figure 1. (B) The SLO/PFOD4 strain (Table 1) was tested for CMT efficiency
(top) and hemolytic titers (bottom) and presented as described for Figure 1. An ‘*’ indicates that
CMT is significantly lower than WT (P<0.05). N.D. denotes the limit of detection for hemolytic
activity using an undiluted sample. The data presented represent the mean and the standard
deviation of the mean derived from at least three independent experiments.
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A specific region of SLO Domain 4 is required for CMT: Further inspection of the
sequence differences between SLO and PFO domain 4 revealed that non-conserved
amino acid changes occurred in clusters (Figure 2). To ascertain if CMT activity would
be restored to the SLO/PFOD4 expressing strain, several mutants were made by swapping
PFO sequence with the corresponding SLO sequence in the areas with clusters of
difference (SLO/PFOD4-swap1, SLO/PFOD4-swap2, and SLO/PFOD4-swap3, Table 1).

The

clusters of variable sequence exist between the second and third cholesterol-binding loop
and near the first cholesterol-binding loop (Figure 6). Similar to WT SLO, the cluster
swap mutant proteins SLO/PFOD4-swap1, SLO/PFOD4-swap2 and, SLO/PFOD4-swap3 were
localized to the Triton X-100 insoluble membrane fraction in the absence and presence of
mβc, although lowering the levels of cholesterol in the membrane does reduce protein
binding (Figure 7A). The cluster swap mutant proteins in culture supernatants also had
hemolytic titers similar to that of WT SLO (Figure 7B). The capability of the cluster
swap expressing strains to translocate SPN was assessed after an infection of A549 cells.
Similar to the SLO- and SLO/PFOD4 strains, the SLO/PFOD4-swap1 expressing strain
translocated significantly less SPN than WT (Figure 7B; P<0.05). In contrast, both the
SLO/PFOD4-swap2 and SLO/PFOD4-swap3 strains regained the ability to translocate SPN at
levels significantly higher than the SLO/PFOD4 strain (Figure 7B; P<0.05). Hence,
although domain 4 of SLO and PFO share a high degree of similarity, there are specific
residues near the third cholesterol-binding loop that are necessary for CMT competency.
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Figure 6: Features of PFO domain 4: (A) A cartoon representation of the resolved PFO crystal
structure is shown. The protein secondary structures are represented as coils for α-helices and as
arrows for β-sheets. (B) The domain 4 structure of PFO is magnified to illustrate specific
portions of the protein. The cholesterol binding loops are at the bottom of domain 4. The yellow
color represents the leucine residue located at the tip of the first cholesterol binding loop, the blue
color represents the alanine residue located at the tip of the second cholesterol binding loop, and
the red color represents the alanine residue located at the tip of the third cholesterol binding loop.
Several mutations in domain 4 were made to assess the ability to restore CMT activity to the
SLO/PFOD4 chimera. The residues changed in the swap mutants are shown on the domain 4
structure.

The SLO/PFOD4-swap1 residue changes are shown in orange, the SLO/PFOD4-swap2

residue changes are shown in brown, and the SLO/PFOD4-swap3 residue changes are shown in cyan.
All the images were generated using PyMOL and the domain 4 images are shown in the same
orientation.
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Figure 7: Domain 4 of SLO provides the specificity to restore CMT to the SLO/PFOD4
mutant. (A) Untreated and methyl-β-cyclodextrin treated A549 cells were infected for 3.75 hrs
and the cells were then subjected to Triton X-100 fractionation. A Western blot analysis is shown
and presented as described for Figure 1. (B) The indicated strains (Table 1) were assessed for
CMT efficiency (top) and hemolytic titers (bottom) and presented as described for Figure 1. An
‘*’ indicates that CMT is significantly lower than WT (P<0.05) and an ‘**’ indicates that CMT is
significantly higher than the SLO/PFOD4 strain (P<0.05). N.D. denotes the limit of detection for
hemolytic activity using an undiluted sample. The data presented represent the mean and the
standard deviation of the mean derived from at least three independent experiments.
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The domain 4 and N-terminal extension of SLO are unable to conduct CMT: Previous
reports show that the SLO N-terminal extension is required for CMT (23, 24). The data
in this report indicate that binding to the membrane is necessary; however, a specific
primary structure allows SLO to bind the host cell membrane properly. To assess if these
two SLO structures can allow PFO to translocate SPN, the N-terminal extension of SLO
was grafted onto the primary structure of PFO, which encodes domains 1, 2, and 3,
followed by the SLO domain 4 sequence (SLONT;D4/PFO, Table1). The SLONT;D4/PFO
strain was assessed for CMT efficiency following a 3.75 hour A549 cell infection. The
WT strain was CMT-competent, in contrast SLONT;D4 was CMT deficient similar to the
SLO- strain (Figure 8). Thus although both structures are necessary for CMT, neither
was sufficient to convert PFO into a CMT-competent protein.
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Figure 8: The N-terminal extension and domain 4 of SLO are unable to make PFO CMTcompetent. The indicated strains (Table 1) were tested for CMT efficiency. An ‘*’ indicates that
CMT is significantly lower than WT (P<0.05). The data presented represent the mean and the
standard deviation of the mean derived from at least three independent experiments.
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Binding to cholesterol is not crucial for CMT: The inability of the SLO/PFOD4 strain to
translocate SPN calls into question the role of cholesterol during CMT.

To begin

assessing the necessity for cholesterol in CMT, A549 cells treated with mβc were
infected with WT S. pyogenes. The levels of cholesterol removed during the treatment of
mβc permit SLO to maintain membrane binding (Figure 5A) and do not affect CMT
(Figure 9A). Previous studies demonstrate that mutating a specific loop residue in SLO
and other cytolysins disrupt cholesterol binding (6, 21). Based on these studies, two
strains expressing a mutation the first cholesterol-binding loop were generated (SLOL565G
and SLOL565D, Table 1) to clarify if binding to cholesterol is necessary for CMT. As
expected, neither mutant was able to lyse rabbit erythrocytes due to the inability to bind
to cholesterol.

The SLOL565G strain did translocate SPN at levels that were not

statistically significant from WT the levels of CMT (Figure 9B). The SLOL565D strain did
translocate SPN at levels significantly higher than the SLO- strain (Figure 9B; P<0.05),
although at levels slightly reduced from the WT strain. In total, these data suggest that
although cholesterol was not necessary it does enhance the efficiency of SPN
translocation.
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Cholesterol increases the efficiency of CMT.

(A) Untreated and methyl-β-

cyclodextrin treated A549 cells were infected for 3.75 hrs with the WT strain and tests for CMT
efficiency as described for Figure 1. (B) The indicated strains (Table 1) were assessed for CMT
efficiency (top) and hemolytic titers (bottom) and presented as described for Figure 1. An ‘*’
indicates that CMT is significantly higher than the SLO- (P<0.05). N.D. denotes the limit of
detection for hemolytic activity using an undiluted sample. The data presented represent the
mean and the standard deviation of the mean derived from at least three independent experiments.
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DISCUSSION

While there is a high degree of structural similarities between the CDCs, the
differences in the primary sequence appear to be important in the ability of the cytolysin
to function in CMT. In this report, we demonstrate that without domain 4 SLO is unable
to bind to the membrane and unable to conduct CMT.

However, binding to the

membrane via domain 4 from ILY and PFO cannot restore CMT. The inability of
domain 4 from the related cytolysins to permit CMT suggests that SLO may bind to an
alternative and currently unidentified host cell membrane receptor.

Thus, although

binding is important for CMT there are specific interactions between domain 4 of SLO
and the membrane that are not reproduced in the presence of domain 4 from other
cytolysins.
Expressing domain 4 from ILY in place of the native SLO sequence was not
adequate for CMT. The domain 4 residues of ILY are too divergent to substitute for
SLO. However, a previous report suggests that changing the three variant residues of the
ILY undecapeptide is enough to alter the target cell specificity of the cytolysin making it
similar to SLO (26). Generating the same changes as reported (26) in the sequence of the
variant ILY undecapeptide, in the context of the SLO/ILY domain 4 chimera, could not
restore CMT. Thus even though changing the undecapeptide sequence may change the
specificity of ILY these changes are not enough to overcome the inability of the
SLO/ILY domain 4 protein to make the proper contacts with the membrane.
In contrast to ILY, SLO and PFO share a large degree of primary structure
similarity in the 110 amino acid region of domain 4 and there are 28 non-conserved
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changes between the two proteins in this domain. Yet these changes were enough to
prevent the SLO/PFO domain 4 chimera from making the appropriate contacts with the
membrane.

The majority of the differences exist between the second and third

cholesterol-binding loop, with a small group of residue changes near the first cholesterolbinding loop. Replacing the PFO residues near the first cholesterol-binding loop with
residues from SLO, in the context of the SLO/PFO domain 4 chimera (SLO/PFOD4-swap1),
did not reestablish WT SLO levels of CMT. The SLO/PFOD4-swap1 protein could bind to
the membrane but the strain expressing the protein could not conduct CMT. However,
another domain 4 swap protein, which had four residue changes close to the first
cholesterol-binding loop, eliminates both membrane binding by the protein and SPN
translocation by the strain, similar to the SLOΔD4 strain (data not shown).

Hence,

replacement of the residues near the first cholesterol-binding loop in the SLO/PFO
domain 4 chimera cannot reinstate CMT. On the other hand, replacing the residues
between the second and third cholesterol-binding loop significantly increases the ability
of the SLO/PFOD4-swap2 and SLO/PFOD4-swap3 to carry out CMT. This area has the highest
number of non-conserved residue changes between SLO and PFO in domain 4. The
capacity of the strains, which express these protein mutants, to conduct CMT indicates
that the residues close to the third cholesterol-binding loop in SLO domain 4 are likely
required for binding to an unknown membrane receptor.
Cholesterol must be present in the membrane for domain 4 of PFO to bind (7, 16).
Treating cells with mβc diminishes the ability of SLO/PFO domain 4 protein to bind to
the membrane indicating it has the cholesterol binding characteristics of PFO. The
inability of the SLO/PFO domain 4 strain to translocate SPN also suggests that SLO and
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PFO bind to the membrane in a dissimilar manner. An earlier report demonstrates that
SLO, unlike PFO, can bind to membranes with reduced amounts of cholesterol (10). In
addition, the SLO requirement for cholesterol pertains to its ability to form pores in the
membrane and requires the presence of the cholesterol binding loops (6, 10). The ability
of WT S. pyogenes to conduct CMT in the presence of mβc indicates that decreasing the
levels of cholesterol in the membrane does not affect the process. Furthermore, unlike
the SLO/PFO domain 4 strain mutating the main cholesterol-binding loop of SLO does
not abolish CMT. A earlier report indicates that mutating the main cholesterol binding
loop of cytolysins produces a protein that cannot assemble oligomers and is locked in the
monomer state (34). Hence, the reduced ability of the SLOL565D strain to translocate SPN
suggests that it is similar to a monomer-locked mutant (23). This indicates that similar to
oligomerization, cholesterol enhances CMT.
While the SLO N-terminal extension and D4 primary structures are necessary for
CMT, they are not sufficient to make PFO a CMT-competent translocator. Thus, while
these two structures may make contact with an unknown receptor, the remaining primary
sequence of SLO might bind to SPN. Alternatively, the N-terminal extension might
adopt a specific conformation when it is contact with either domain 1, 2, or 3 of SLO.
Overall, the data suggests that in addition to cholesterol, SLO binds to an
unknown receptor in the host cell membrane likely using the region near the third
cholesterol-binding loop.

Furthermore, contacts with cholesterol in the membrane

enhance CMT by allowing oligomerization to occur.
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MATERIAL AND METHODS

Table 2. Primers used in this study.
Name

Sequence/Description a

NM091p

TACGCGAATGTTTCTAACATTTCCCTTGAAACGGAGAGT

NM092p

AAAGTACTAGAGTGCACCGGCTTAGCTTGGGAATGGTGGCGACTG
Inverse PCR mutagenesis primers for SLO/ILYD4-ECW mutant

NM133p

AAAAAACTCGAGGCCTATGGTCGAACTGTTTTTGTCAAAC

NM134p

CTTTGTCGTCATAATTGATTTCATCCCAAAGGATTTC

NM135p

CAATTATGACGACAAAGGAAAAGAAGTTATTACTAAAC

NM136p

AAAAAAATCGATAGCTGGTTATTCTATAAGACAAAACAC
Sequence overlap extension mutagenesis primers used for SLO/PFOD4-swap1

NM123p

ATCTCTTTCGTCTATAACTTTTCTCCACCATTCCCA

NM124p

GTTAAATTATCTAAAGAAATAAATGTTTCAATATGG
Inverse PCR mutagenesis primers for SLO/PFOD4-swap2

NM125p

TTTATCATAATAATTTCCATCCCAACGTTTATG

NM126p

ACAGCTCCATATTCAACAGTAATACCTCTTGGAGCTAATGCA
Inverse PCR mutagenesis primers for SLO/PFOD4-swap3

NM111p

ACCATATGGGCTGTCGGTTGATCCTGAGAT

NM1112p

TCGATTACTTATAAGTAGGACTGGTTCAAG
Inverse PCR mutagenesis primers for SLOL565D

NM113p

ACCATATGGGCTCCCGGTTGATCCTGAGAT

NM114p

TTGAGCAACATAGTCGCCTTGATGAGACAGGTT
Inverse PCR mutagenesis primers for SLOL565G

a

Allelic replacement was used to substitute the endogenous allele in WT JRS4 with the

mutant alleles
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Bacterial Strains: Molecular cloning experiments utilized Escherichia coli TOP10
cultured in Luria-Bertani broth at 37°C. S. pyogenes utilized were of M serotype 6 strain
JRS4. Routine culture of S. pyogenes occurred at 37°C in Bacto™ Todd-Hewitt broth
(ThyB) supplemented with 0.2% BBL™ autolysed yeast extract. At appropriate times,
erythromycin was added to media to final concentrations of 750 μg/ml for E. coli and 1
μg/ml for S. pyogenes.

Manipulation and computational analyses of DNA: Transformation of E. coli used the
method of Kushner (Kushner 1978) and plasmid DNA was isolated from E. coli using
standard techniques.

S. pyogenes was transformed by electroporation as previously

described (4). Restriction endonucleases, ligases, and polymerases were used according
to manufacturer’s recommendations. The fidelity of all DNA sequences created by
polymerase chain reaction (PCR) was validated by DNA sequencing analyses performed
by a commercial vendor (Genewiz; South Plainfield, NJ, USA).

Construction of SLO domain 4 mutants: A custom gene synthesis approach was used
to generate the nucleotide coding sequence of the SLO/PFOD4, SLO/ILYD4, and
SLONT;D4/PFO mutants in the pUC57 vector (Genscript; Piscataway, NJ, USA). The
nucleotide sequences were then removed from pUC57 and inserted into the pJRS233,
suicide shuttle vector containing an erythromycin resistance cassette, using the restriction
endonuclease enzymes XhoI and ClaI. An inverse PCR method was used to generate the
SLO/ILYD4-ECW mutant from the SLO/ILYD4 nucleotide sequence present in pJRS233,
using the primers NM091p and NM092p. Sequence overlap extension mutagenesis (PCR
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SOEing, (17)) was used to make the SLO/PFOD4-swap1 mutant from the SLO/PFOD4
nucleotide sequence present in pJRS233. The primer pair NM133 and NM134p and the
primer pair NM135p and NM136p were used to generate two PCR products. The two
~0.5 kb PCR products were purified and both were added to a subsequence amplification
reaction, which used the primers NM133p and NM136p. The product of the second
round PCR was cleaved with XhoI and ClaI and inserted into pJRS233. The inverse PCR
method was used to generate the SLO/PFOD4-swap2 and SLO/PFOD4-swap3 mutants from the
SLO/PFOD4 nucleotide sequence present in pJRS233, using the primers NM123p and
NM124p and the primers NM125p and NM126p, respectively. The cholesterol-binding
mutants, SLOL565D and SLOL565G, were made using the inverse PCR method from the WT
slo nucleotide sequence present in pJRS233, using the primer set NM111p and 112 and
the primer set NM113p and 114p, respectively. The JRS4 WT slo allele was replaced
with the mutants as previously described (19). All primer sequences are listed in Table 2
with restriction endonuclease site underlined.

Analysis of hemolytic activity: Cell free overnight S. pyogenes culture supernatants
were used to measure the ability of various SLO mutants to lyse rabbit defibrinated
erythrocytes (22). Where noted, human erythrocytes were collected from a volunteer and
used to assess hemolytic activity. Hemolytic titer is defined as the reciprocal of the
dilution that produced 50% lysis (22, 24).

The limit of detection for hemolysis is

specified by a designation of not detected (N.D.), which meant that lysis did not occur in
the presence of undiluted supernatant.
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Analysis of CMT:

Analysis of CMT was conducted as previously described (9, 24).

Briefly, A549 cells (ATCC CCL-185) were grown in 75 cm2 tissue culture flasks in the
presence of Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 50 mM
HEPES, 8 mM L-glutamine, and 10% fetal bovine serum. The confluent cells were
infected with various streptococcal strains as mentioned in the text. To prepare for the
infection, streptococcal cultures were grown overnight in ThyB, subjected to
centrifugation, washed twice with phosphate saline buffer (PBS), and resuspend in prewarmed medium to an OD600 of 0.66. The A549 cells were incubated with 1 mL of the
resuspended streptococcal strains plus 14 mL of fresh medium for 3.75 hrs at 37°C in the
presence of 5% CO2. After the infection, the culture supernatant was collected and filter
sterilized. The A549 cells were washed twice with PBS, lysed with a 0.05% saponinprotease inhibitor mixture, and the cytosolic fractions prepared as previously described
(22, 24). The SPN activity in the A549 cytosolic fraction was analyzed by measuring
cleavage of β-NAD+ as described earlier (22, 24).

Where indicated, methyl-β-

cyclodextrin (cat.#C4555, Sigma) was added to media for 60 minutes prior to infection
by streptococcal strains.

Statistical Analysis:

Any differences in the mean values of CMT translocation

efficiencies compared between various mutant and WT strains were tested for
significance by the unpaired t-test (13) and P-values less than 0.05 were considered
significant.
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A549 cell membrane extraction: Cell membranes were prepared and analyzed as
previously described (22). In brief, after 3.75 hr infection, the medium was removed
from the A549 cells and the cells were washed twice with ice-cold Tris-buffered saline
(pH 7.5). The cells were lysed in TBS containing 1% Triton X-100 (Sigma), scraped
from the flask, transferred to a tube, and incubated at 4°C for 30 min. The suspension
was then subjected to centrifugation (19900 x g, 15 min, 4°C) and the soluble material
was transferred to a new tube and the insoluble material was resuspended in SDS sample
buffer (100 mM Tris-HCl [pH 6.8]; 20 mM DTT; 4% SDS [weight/vol]; 20% glycerol
[vol/vol]; and 0.2% bromophenol blue [weight/vol]). The soluble material was diluted
1:4 in SDS sample buffer. The soluble and insoluble fractions were then analyzed by a
Western blot using anti-SLO antiserum.

Where indicated, methyl-β-cyclodextrin

(cat.#C4555, Sigma) was added to media for 60 minutes prior to infection by
streptococcal strains.
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CONCLUSIONS

Cytolysin-mediated translocation appears to be a specific process that uses
streptolysin O (SLO) to transport the S. pyogenes NAD+- glycohydrolase (SPN) into host
cells. Since SLO is a member of the cholesterol-dependent cytolysin family of proteins,
there was a proposal that CMT might be a general mechanism used by the cytolysins to
translocate effector proteins.

However, during the course of this work accounts

describing a similar mechanism in other species of Gram-positive bacteria have not been
published. Prior to and while the studies in this report were occurring, several papers
were published revealing the following details: CMT has a role in virulence, CMT cannot
occur when a related cytolysin is expressed in lieu of SLO, SLO can differentiate
between secreted S. pyogenes substrates, SPN is a strict NAD+-glycohydrolase, and
expression of SPN requires the presence of an endogenous inhibitor that protects against
the NAD+-glycohydrolase activity (1, 2, 4, 5, 7, 8, 10, 11).
The major aspects of CMT described in these reports were that 1) CMT can occur
in the absence of SLO pore formation, 2) cytotoxicity requires both SLO pore formation
and SPN translocation, 3) binding to the host cell membrane is necessary, but general
binding to the membrane is insufficient for CMT, 4) a specific region of SLO domain 4 is
important for CMT, 5) reducing the levels of cholesterol in the membrane with an
inhibitor does not affect CMT, and 6) a chimera expressing the SLO N-terminal
extension and SLO domain 4 with the primary structure of PFO does not produce a
CMT-competent protein. Although these results are salient, they do not provide a distinct
mechanism for how SLO translocates SPN into the host cell cytosol.
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The original CMT model proposes that SPN enters the host cell through the
lumen of the SLO pore; however, prior data suggests the method of translocation is more
complicated (5, 10). To further characterize the mechanism of CMT, the experiments
described in this thesis were conducted. In Chapter 2, the purpose of the experiments
was to answer the following questions: 1) Is pore formation by SLO required for SPN
translocation? 2) Is SLO oligomerization necessary for CMT? 3) Does cytotoxicity
require SLO pore formation? The data from these experiments and others were presented
in this chapter and published to advance the knowledge pertaining to CMT (9). A strain
expressing a prepore-locked SLO protein was capable of SPN translocation even though
the protein was unable to form pores in A549 cells and rabbit erythrocytes.

This

indicated that SLO pore formation was not necessary for CMT. Additionally, a strain
expressing a monomer-locked SLO protein could also translocate SPN but not as
effectively as the prepore-locked strain. Thus, this data supports the concept that pore
formation is not required and demonstrated that SLO oligomerization enhances CMT.
Although the prepore-locked strain translocates SPN, this strain is non-cytotoxic. A coinfection with prepore-locked and SPN- strains partially restored the levels of
cytotoxicity, suggesting that the toxic effects were most efficient when SPN translocation
and SLO pore formation were coupled. In total, these results demonstrated that the two
activities of SLO, pore formation and SPN translocation, could be uncoupled but that
pairing of these activities augments S. pyogenes cytotoxicity.
Although the results from Chapter 2 dramatically shift the CMT paradigm, the
data did not provide a lucid mechanism for translocation.

We began a series of

experiments in Chapter 3 to assess the role of host cell endocytosis in CMT and to detect
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an interaction between SPN and SLO.

In particular, we were interested in using

inhibitors identified as being effective against various proteins involved in host cell
endocytosis. We revealed that an inhibitor of PI3-kinase, LY294002, does not affect
SPN translocation. In conjunction with data presented in Chapter 2, which showed an
inhibitor of actin polymerization does not affect CMT, this strongly suggests that
clathrin-dependent endocytosis is not involved in the translocation of SPN. There are
several recognized pathways for clathrin-independent endocytosis in host cells such as
caveolae-mediated endocytosis (3).

Many of these pathways begin in specific cell

membrane domains and use various kinases to signal into the host cell. Cholesterolenriched domains of the membrane are sites of potential endocytosis and using nystatin, a
compound that sequesters the sterol, we showed that there was no decrease in the levels
of SPN translocation.

Preliminary data also suggests that CMT is unaffected by

inhibition of protein kinase C, an indication that caveolae-mediated endocytosis might
not be involved. Although, we did not determine if an alternate host cell endocytosis
pathway is involved in CMT, we examined the ability of SLO and SPN to interact in a
bacterial two-hybrid system. We did not detect an interaction between SPN and SLO in
this system; however, we did detect binding between SPN and the immunity factor for
SPN. The data presented in Chapter 2 illustrated that the monomer-locked SLO strain
could translocate SPN suggesting that these two proteins could interact as individual
polypeptides. Hence, SPN might only bind to SLO in the presence of an unknown
accessory protein present in the host cell membrane. Attempts to detect an interaction
between the putative protein SpyM3-0131 and SLO or SPN were unsuccessful. In total,
the results from Chapter 3 suggest a clathrin- and caveolae-independent endocytosis
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pathway of the host cell might participate in CMT and that an accessory protein may be
necessary to allow SPN and SLO to bind.
To support our mission of defining a mechanism for CMT, we initiated studies to
determine if there was specificity involved in the binding of SLO domain 4 to the host
cell membrane. The goal of the experiments in Chapter 3 was to address the following
set of questions: 1) Is binding to the membrane necessary for CMT? 2) Can the domain 4
primary structure of a related cytolysin functionally replace domain 4 of SLO and allow
the protein chimera to perform CMT? 3) Is the presence of cholesterol required during
SPN translocation? The results from experiments pertaining to these questions were
presented in this chapter and will be submitted for publication. Deletion of SLO domain
4 prevented SPN translocation, an indication that membrane binding is necessary.
However, replacing the native SLO domain 4 amino acid sequence with that of ILY,
which binds to the membrane protein CD59, or with PFO, which binds to cholesterol, did
not restore CMT suggesting that binding to the host cell membrane is not sufficient.
Since SLO and PFO share a high degree of similarity in the domain 4 region, we made
three strains in which portions of the PFO domain 4 sequence were replaced with SLO
sequence in the background of the SLO/PFOD4 chimera. After restoring the native SLO
sequence to an area of domain 4 that has the highest number of non-conversed amino
acid differences between the two cytolysins, two of the strains expressing the sequence
swaps in the SLO/PFOD4 chimera regained the ability to translocate SPN. This result
suggests that this specific region, closest to the third cholesterol-binding loop, of SLO
domain 4 makes important contacts with the host cell membrane.

Given that the

SLO/PFOD4 strain failed to translocate SPN, the requirement for cholesterol in CMT was
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in question. We demonstrated that treatment of host cells with methyl-β-cyclodextrin
(mβc) sufficiently reduced the levels of cholesterol in the membrane and eliminated the
SLO/PFOD4 chimera localization to membrane fractions; however, wild type (WT) SLO
continued to localize to membrane fractions after identical mβc treatments. These results
suggest that SLO domain 4 has a higher tolerance for diminished membrane cholesterol
than PFO domain 4. Furthermore, we discovered that treatment of host cells with mβc
did not alter the SPN translocation capability of WT S. pyogenes. To further probe the
role of cholesterol, we generated S. pyogenes strains that expressed a point mutation in
the main domain 4 loop responsible for the ability of cytolysins to bind to cholesterol.
We observed that the CMT levels of the SLOL565G strain are not statistically significant
from those of WT. In addition, the SLOL565D strain also could translocate SPN, however,
the levels were slightly lower than WT. A previous report indicates that point mutations
in the main cholesterol-binding loop create cytolysins that are locked in the monomer
state (12). Thus, these studies suggest that although cholesterol is not required it does
enhance CMT.
In summary, the experiments detailed in this thesis demonstrate the intricacy of
CMT. This process begins with adherence of S. pyogenes to the surface of host cells,
followed by the expression and secretion of SLO and SPN near the host cell membrane.
SLO binds to the host cell membrane via domain 4, in which a specific region near the
third cholesterol-binding loop is necessary. After binding, SLO forms oligomers and in
the absence of a pore translocates SPN into the host cell cytosol.
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FUTURE DIRECTIONS

To gain a complete comprehension of the specific mechanism of CMT and the
role of this secretion system in S. pyogenes pathogenesis, numerous experiments must be
completed. The major question that remained unresolved at the end of my research in
Chapter 2 is the following, how does SLO translocate SPN in the absence of a pore? The
experiments we began in Chapter 3 to address this question provided some useful details.
To examine this question using the various inhibitors of host cell endocytosis, attempts to
use reduced concentrations of the compounds must occur to decrease the potentially toxic
affect on S. pyogenes SPN secretion.

If these attempts are unsuccessful, cell lines

expressing mutations in proteins involved in host cell endocytosis can help determine the
effect on CMT. Alternatively, RNA interference can target transcripts in cell lines to
decrease the levels of protein expression and ascertain if there is an effect on CMT.
Experiments in which A549 cells express the dominant negative mutant dynaminK44A will
help assess how the activity of this GTPase affects CMT. Dominant negative mutants of
Arf1 and Arf6 could also provide insights into the role of vesicle trafficking in CMT.
Expression of short interfering RNA (siRNA) constructs that would decrease the
expression of caveolin-1 could help to determine whether caveolae-mediated endocytosis
plays a role in CMT. Other siRNA constructs that would possibly yield information
about the involvement of host cell endocytosis in CMT are tyrosine kinase (i.e. Src, Fyn)
and small GTPase (i.e. cdc42, rhoA, rac) targets. These initial experiments should aid in
elucidating the role of the host cell in CMT. Other prospective experiments include
isolating endosomes at various time points from infected cells to determine the type of
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vesicle SLO and SPN may inhabit by identifying known markers or tagging SLO and
SPN with different fluorophores with the goal of using microscopy to follow CMT.
The necessity for additional S. pyogenes secreted proteins in CMT is
undetermined. To assess this possibility, the entire CMT operon (spn, ifs, slo) could be
expressed heterologously from a plasmid in Lactococcus lactis. Such a construct with the
sequence of the entire operon currently exists in the shuttle vector pABG5. Since L.
lactis does not normally adhere to host cells, an S. pyogenes adhesion, such as M protein,
would also need to be expressed in the bacteria. Alternatively, purified SLO and SPN
can be used to reconstitute CMT. However, the success of this procedure will require
precise determination of the concentrations of each protein. To prevent complete lysis of
the cells by WT SLO, the prepore-locked SLO could be used in these studies. The ability
to recreate the system in the absence of S. pyogenes would suggest that no other bacterial
factors are necessary and that once SLO and SPN are in close proximity to the host cell
membrane translocation can occur. In my opinion, the ability to reconstitute CMT with
purified proteins in the absence of S. pyogenes would be useful since future research
could occur without concern regarding bacterial adherence or variable protein secretion.
However, based on previous data it may not be possible to use a purified protein system
for CMT if the localized concentrations of SPN and SLO near the host cell membrane are
not optimal (8). The process of CMT appears to be extremely coordinated and attempts
to develop of protein-based system may not succeed. In Chapter 3, mutating the SpeB
cleavage site in the N-terminal extension of SLO abrogates CMT. This suggests that
processing of this site occurs before SPN translocation. Other S. pyogenes strains that
could help elucidate the role of this site in CMT include a mutant expressing an in-frame
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deletion in speB, a point mutation in the active site of speB (C192S), and additional
truncations of the slo N-terminal extension (i.e. SpeB cleaved version of slo). The SpeB
cleavage site mutant may have an improperly folded SLO N-terminal extension, which
could be the basis for the decrease in CMT. It is also possible that a host cell protease
(i.e. furin), and not SpeB, cleaves this site before CMT can occur. An infection of host
cells in the presence of a cysteine protease inhibitor, E64, would help assess this
possibility. However, in the Triton X-100 studies conducted during this thesis there was
not any evidence of a cleaved form of SLO in the membrane fractions following an
infection with S. pyogenes. Thus in my opinion, the inability of the SpeB cleavage site
mutant to translocate SPN is likely a result of misfolding and any additional changes to
the SLO N-terminal extension will likely halt the ability of SLO to translocate SPN.
Although the N-terminal extension is necessary, its role in CMT continues to be
ambiguous. The bacterial two-hybrid system in Chapter 3 did not detect an interaction
between SPN and the SLO N-terminal extension. It is possible that this SLO primary
structure is binding to a component of the host cell membrane to increase the efficiency
of CMT. Within the 66 amino acid sequence, there are a number of charged and polar
residues, including a cluster of six charged residues that occur near the end of the
sequence. The absence of hydrophobic residue clusters in the N-terminal extension
suggests that it is probably unstructured until it binds to an unknown molecule. To
continue probing the significance of this region, mutational analysis could test the
importance of each of the N-terminal extension charged residues. Those mutants that
alter the ability of SLO to perform CMT should also be tested for defects in membrane
binding. Future experiments could use the data obtained from the N-terminal extension
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studies to construct fluorescently labeled peptides, to be used in enzyme-linked
immunosorbent assays or fluorescence polarization assay to measure binding to purified
host membrane proteins and host membrane lipids in liposomes.
Towards the end of Chapter 4, the ability of the SLO N-terminal extension and
the domain 4 primary structure to convert perfringolysin O (PFO) into a CMT-competent
protein failed. Both of these components of SLO are known to be necessary but not
sufficient for CMT. In this chimera protein, domain 4 of SLO is likely making the proper
contacts with the host cell membrane. It is possible that once SLO binds to the host
membrane the conformation changes in the remainder of the molecule repositions the Nterminal extension and prepares it for binding to either SPN or a co-receptor in the host
membrane. SLO and PFO are 67% identical and 83% similar across all four domains of
the proteins (6). However, based on our domain 4 studies this high level of similarity is
not sufficient for PFO to translocate SPN.

Thus, the primary structure differences

between SLO and PFO are sufficient to hinder the capability of most SLO/PFO chimera
proteins to conduct CMT. Mutagenesis studies could be used to replace PFO sequence
with SLO sequence in this chimera. The areas with the largest number of amino acid
difference between SLO and PFO should be targeted for replacement in the chimera
protein. Overall, based on this data, future SLO mutagenesis studies should possibility
only change a few residues at a time to assess accurately the effects the mutations on the
translocation of SPN.
As of yet, we have been unable to detect an interaction between SPN and SLO. It
is possible that SLO must bind to its receptor before binding to SPN. In Chapter 4, we
identified a specific primary structure in SLO domain 4, near the third cholesterol-
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binding loop, that can restore CMT suggesting this region of SLO is important for host
cell membrane binding. Although SLO can bind to cholesterol, there is likely a coreceptor involved in the binding of the cytolysin. To begin the process of identifying the
potential receptor, purified His-tagged WT and prepore-locked SLO can be immobilized
on a column filled with cobalt chelate resin and isolated host cell membrane fractions
poured into the column. Any proteins isolated with SLO and visible on a stained SDSpolyacrylamide gel can be identified by sequencing. The pBAD-geneIIIb expression
plasmids containing the sequence of WT and prepore-locked slo already exist and have
been used to produce purified proteins (9). Alternatively, purified His-tagged preporelocked SLO can be added to cells, followed by treatment with a cross-linker, and
identification of potential receptors. To assess if a glycolipid or glycoprotein might be
involved, host cells can be enzymatically treated with various endoglycosidase to assess
the effect on CMT, however, there is a possibility that this would affect S. pyogenes
adherence. Another method to identify a potential lipid receptor is the protein lipid
overlay technique, in which serial dilutions of various lipids are blotted onto
nitrocellulose membrane, followed by incubation with purified protein, and detection
using an immunoblot. It is possible the SPN also binds to an unknown membrane
molecule. To assess this option, analysis of purified SPN in the assays listed above can
occur concurrently with SLO. In my opinion, the future studies of CMT should focus on
identification of the SLO receptor. This would permit more in depth studies on the
mechanism of translocation to continue.
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